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The objective of this dissertation was to systematically investigate the 
hemodynamic response to exercise in heart failure with reduced ejection fraction 
(HFrEF) and healthy individuals of a similar age, with an emphasis on how the 
sympathetic nervous system (SNS) may contribute to the dysregulation of the 
cardiovascular system in this cohort. The first study aimed to determine how varying 
levels of metaboreceptor activation alters the mean arterial pressure (MAP) response as 
well as the degree in which cardiac output (CO) and systemic vascular conductance 
(SVC) contribute to the metaboreflex-induced increase in MAP.  We observed similar 
increases in MAP induced by metaboreceptor activation in both groups; however, this 
response was driven primarily by increases in CO in the control group and reductions in 
SVC in the HFrEF group. These data suggest a preserved role of the metaboreflex-
induced increase in MAP in HFrEF, but suggest that this response is governed by the 
peripheral circulation in this cohort, a maladaptation that may exacerbate systolic 
dysfunction through an increase in afterload. The second study of this dissertation was 
focused on investigating the peripheral vasodilatory and hyperemic response to exercise 
in isolation of central hemodynamic limitations in both the upper and lower limbs. This 
study documented an impaired hyperemic response to both static-intermittent handgrip 
exercise as well as dynamic single-leg knee-extensor exercise in HFrEF patients - 
impairments primarily attributed to vasodilatory dysfunction, as the increase in MAP 
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induced by these exercise modalities was preserved compared to healthy individuals. 
Together, these findings have identified a significant attenuation of the exercise-induced 
hyperemic response during both upper and lower limb exercise, implicating maladaptions 
in the peripheral hemodynamic response to exercise as a potential contributor limiting 
exercise capacity in this patient group. The third study sought to address the contribution 
of the alpha-adrenergic receptor pathway in the regulation of blood flow to exercising 
skeletal muscle in HFrEF patients. At rest, alpha-1-adrenergic receptor vasoconstriction 
induced by local intra-arterial infusion of phenylephrine (PE) was reduced in HFrEF 
compared to control subjects. During exercise, the vasoconstrictor responsiveness to PE 
was significantly attenuated in the control group and preserved in HFrEF patients 
compared to rest. Additionally, nonspecific alpha-adrenergic receptor antagonism 
induced by local intra-arterial infusion of phentolamine increased blood flow to a greater 
degree in HFrEF compared to the control subjects, both at rest and during exercise. 
Together, these findings demonstrate a marked contribution of alpha-adrenergic receptor 
restraint of leg blood flow in HFrEF patients during exercise. Collectively, these three 
studies have provided new insight into the role the SNS and peripheral hemodynamics 
play in the maladaptive cardiovascular response to exercise displayed in patients with 
HFrEF, further implicating the peripheral expression of SNS activity as a primary 
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In the United States, chronic heart failure (CHF) constitutes one of the leading 
causes of mortality, accounting for roughly one third of all deaths from cardiovascular 
causes with a 50% 5-year mortality rate (52). Additionally, the American Heart 
Association estimates that more than 5 million people in the United States alone have 
CHF, with roughly 550,000 new cases diagnosed each year (52). CHF is a disease that 
has many different origins and is typically the most severe manifestation of almost every 
form of cardiac disease, including myocardial infarction, coronary atherosclerosis, 
hypertension, congenital heart disease, and cardiomyopathies (27).  
CHF is a pathology which is commonly characterized by left ventricular ejection 
fraction (LVEF), an expression of stroke volume (SV) as a percentage of left ventricular 
end-diastolic volume. While the crudity of LVEF as a measure of left ventricular function 
has been criticized, the association between LVEF and morbidity as well as mortality is 
well established (8, 67). However, CHF is a subjective clinical syndrome which is 
variably defined (34), and, in general, heart failure classification is poorly related to 
LVEF (34). For example, patients with a reduced LVEF may be asymptomatic, while 
severe CHF-related symptoms may be apparent in patients with a “preserved” LVEF. 
Thus, patients with CHF are now further delineated on the basis of LVEF, leading to the 
new nomenclature of heart failure with reduced ejection fraction (HFrEF) or heart failure 
with preserved ejection fraction (HFpEF) (29). 
Autonomic Dysfunction in Heart Failure with Reduced  
Ejection Fraction 
  A hallmark characteristic of patients with HFrEF is heightened sympathetic 
nervous system (SNS) activity, quantified by resting muscle sympathetic nerve activity 
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(MSNA) (16, 32) and plasma norepinephrine (NE) concentration (17), both of which are 
associated with severity (16, 17) and predictive of mortality in HFrEF patients (3, 17). 
Additionally, observations from clinical trials have indicated that exaggerated SNS 
activation appears to precede the development of clinical signs and symptoms of HFrEF 
(17), suggesting that sympathoexcitation plays a role in the genesis and progression of the 
disease. While this increased SNS activity initially serves to improve cardiac function 
and support arterial blood pressure (ABP), it also provokes a sustained peripheral 
vasoconstriction that restrains skeletal muscle blood flow (63, 81). For this reason, the 
evolving model of pathophysiology in CHF has expanded to include the peripheral 
vasculature, where the disease manifests as vascular and skeletal muscle dysfunction 
related to underlying autonomic effects of the disease.  
 One of the principal functional consequences of the exaggerated SNS activation 
and subsequent peripheral vasoconstriction in patients with HFrEF might be the 
worsening of symptoms upon exertion. Indeed, HFrEF patients have been documented to 
have severe exercise intolerance which is associated with the severity of the disease and 
triggers debilitating cases of dyspnea and fatigue (63).  Interestingly,  while central 
hemodynamic abnormalities are, by definition, the fundamental characterization of 
HFrEF, the degree of left ventricular dysfunction does not fully explain the degree of 
exercise intolerance or symptom status in this patient group (4, 22, 36, 65, 68). This 
supports the possibility that peripheral maladaptations may contribute to the exercise 
intolerance in this patient group. Early studies exploring the possible relation between 
exercise intolerance in HFrEF and SNS activity indicated that resting MSNA is 
negatively associated with aerobic capacity in this cohort (42), and patients with HFrEF 
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exhibit an exaggerated increase in MSNA during exercise (37, 43, 60, 62). These novel 
findings raise the question of the functional end-organ consequences of the persistent 
augmentation of MSNA during exercise in HFrEF.  
The Metaboreflex Response to Exercise in Heart Failure with  
Reduced Ejection Fraction 
As mentioned above, accumulating evidence indicates that exercise limitations in 
HFrEF patients are not predominantly due to inadequate left ventricular function, which 
has led to a shift in the investigations probing the mechanisms contributing to exercise 
intolerance in this patient population to the periphery. Recently, Drs. Coats and Piepoli 
have hypothesized that abnormalities arising from the skeletal muscle, specifically the 
sensory nerve fibers that mediate reflex changes triggered by exercise, may contribute to 
the exercise limitations in HFrEF (6, 48). This so-called “muscle hypothesis” of HF 
proposes another cycle of deterioration similar to that of neuroendocrine activation, 
whereby left ventricular dysfunction leads to abnormalities in skeletal muscle metabolism 
and function that contributes to an exaggerated reflex increase in SNS activity.  
 Located within the skeletal muscle, the sensory afferent fibers mediating these 
reflex increases in SNS activity, often termed the “ergoreflex”, consist of group III 
afferent fibers which are predominately mechanically sensitive (mechanoreceptors) and 
group IV afferent fibers (metaboreceptors) which are principally sensitive to metabolites 
produced during exercise (26). These afferent signals are carried to the cardiovascular 
center of the nucleus tractus solitarii (NTS), provoking specific efferent signals to the 
heart and peripheral circulation. Specifically, vagal withdrawal and an increase in SNS 
activity to the heart induces an increase in heart rate, which is accompanied by a 
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sympathetically-mediated increase in SV (1, 7, 44), collectively increasing the perfusion 
pressure generated by the heart. In the periphery, SNS activation helps divert blood flow 
to the exercising skeletal muscle through vasoconstriction of the vasculature perfusing 
less metabolically active tissue (2, 38, 39). Together, these cardiac and vascular responses 
work in concert to increase perfusion of the muscle from which the afferent signals 
emanate (1, 26, 45).   
The extent to which the mechano- and metaboreceptors contribute to the reflex 
increase in SNS activity (as measured by direct recordings of MSNA) in HFrEF patients 
has long been a topic of debate (40, 49). Implementing postexercise circulatory occlusion 
following handgrip exercise, previous studies have documented an increased sensitivity 
of both the mechanoreflex (37) and the metaboreflex (43, 60). However, conflicting 
evidence exists in regards to the metaboreflex, with studies indicating both a blunted (62) 
and a similar (37) increase in MSNA in HFrEF patients compared to healthy individuals. 
Under a closer lens, it appears that these conflicting results can be attributed to the 
modality of handgrip exercise and the intensity of exercise implemented. Indeed, Sterns 
et al. (62) had subjects perform static handgrip exercise to activate the metaboreflex, an 
exercise modality that is not rhythmic in nature, making it difficult to translate these 
finding to physical activity performed by HFrEF patients in everyday life. Furthermore, 
the intensity of rhythmic handgrip exercise implemented by Middlekauff et al. (37) failed 
to significantly increase MSNA during metaboreceptor activation in either HFrEF 
patients or healthy individuals, making it difficult to conclude that there is no difference 
in the metaboreflex control of MSNA between groups. Based on the conflicting findings 
on the role of the metaboreflex in increasing MSNA during physical stress in HFrEF, it is 
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not surprising that studies investigating the impact of this increase in SNS activity on 
ABP responses have been inconclusive as well. Indeed, studies have documented both 
exaggerated (48, 57) and similar (5, 30, 43, 62) increases in ABP during metaboreceptor 
activation in HFrEF patients compared to healthy individuals. The conflicting findings 
from these studies indicate that significant uncertainty still remains as to whether the 
metaboreflex-induced pressor response is altered in HFrEF.  
Additionally, very little is known about the roles cardiac output (CO) and 
systemic vascular conductance (SVC) play in increasing ABP during metaboreceptor 
activation in HFrEF. In a healthy animal model, O’Leary et al. (44) documented that the 
rise in ABP triggered by metaboreceptor activation was solely due to increases in CO 
during low to moderate exercise intensities. Additionally, during near maximal exercise, 
where increases in CO are minimal, Augustyniak et al. (2) documented that a further 
increase in ABP due to metaboreceptor activation was due to a reduction in SVC. This is 
in contrast to findings in an animal model of HF, where reductions in SVC predominately 
contribute to the metaboreflex-induced increase in ABP during all exercise intensities, a 
response likely due to impaired left ventricular function (19). In humans, even less is 
known about the degree in which CO and SVC contribute to the metaboreflex-induced 
increase in ABP in HFrEF. In one of the only studies exploring this topic, Crisafulli et al. 
(7) utilized one moderate intensity of rhythmic handgrip exercise to study this 
relationship in HFrEF and healthy controls, and observed a metaboreflex-induced 
increase in ABP which was predominantly driven by an increase in CO in healthy 
individuals and a reduction in SVC in patients with HFrEF. This has been complemented 
by work indicating an exaggerated increase in diastolic blood pressure during 
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metaboreceptor activation in HFrEF, indirectly indicating a reduction in SVC in this 
patient group (47). While these investigations have shed light on the differing avenues by 
which the metaboreflex increases ABP in HFrEF compared to their healthy counterparts, 
the inclusion of only one moderate intensity workload of handgrip exercise leaves 
unanswered whether the relative contribution of CO and SVC to the exercise pressor 
response varies as a consequence of exercise intensity.   
A more comprehensive understanding of the metaboreflex, and the relative 
contribution of CO and SVC to this reflex response, would add significantly to our 
understanding of the “muscle hypothesis” in HFrEF. Undeniably, an attenuation in the 
rise in CO coupled with an exaggerated reduction in SVC may collectively generate a 
scenario where blood flow to exercising skeletal muscle is potentially compromised due 
to central and peripheral hemodynamic alterations in order to preserve ABP. Indeed, 
reductions in SVC, a measure of systemic vascular tone which also represents the 
nonpulsatile component of arterial afterload (25, 80), may present a further stress to 
cardiac muscle, a stress which is likely vastly minimized in healthy individuals. It follows 
that knowing whether reductions in SVC play a primary role in the metaboreflex-induced 
increases in ABP across a wide array of exercise intensities will indicate at what level of 
work this reflex pathway might become detrimental in increasing perfusion of the 







Peripheral Hemodynamic Response to Exercise in Heart Failure  
with Reduced Ejection Fraction 
While an exaggerated metaboreflex response to exercise may contribute 
importantly to exercise intolerance in HFrEF, these patients may also exhibit a 
fundamental impairment in vasodilatory ability and hyperemia during physical activity. 
Initial evidence for a functional role of impaired peripheral hemodynamics in limiting 
exercise capacity in this cohort was documented during peak cycling exercise, where an 
apparent reduction in leg vascular conductance was observed in patients with HFrEF 
compared to healthy individuals (71-75). However, the use of a large muscle mass 
exercise paradigm presents limitations in distinguishing abnormalities in peripheral 
vasomotor function in HFrEF. When performing exercise, blood flow to exercising 
skeletal muscle is accomplished through an orchestrated series of events which includes  
contributions from both “central”  (i.e. CO) and peripheral (i.e. SVC) portions of the 
cardiovascular system in order to divert blood away from less metabolically active tissue 
towards exercising skeletal muscle. During exercise which recruits a large fraction of 
total body muscle mass, central circulatory factors play an increasingly important role in 
the preservation of ABP (46, 51, 55, 56). Due to impaired left ventricular function, 
patients with HFrEF cannot increase CO to the same level as healthy individuals during 
exercise (63, 75). However, irrespective of cardiac function, there is no difference in the 
observed MAP during peak cycling exercise in HFrEF compared to healthy controls (63). 
This may indicate that a restraint of the exercise-induced increase in SVC plays a 
heightened role in ABP regulation in HFrEF, and may also indicate that the observed 
reduction in leg vascular conductance and associated reduction in perfusion of the 
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exercising skeletal muscle might solely be due to the maintenance of ABP versus 
limitations in vasodilatory capacity in this patient group (63, 75).  
In a small number of studies, the utilization of small muscle mass exercise such as 
dynamic single-leg knee-extensor (KE) and rhythmic handgrip exercise has allowed for a 
more thorough investigation of peripheral vasomotor responses to exercise in HFrEF in 
isolation of the significant cardiac stress and associated confounding effects of ABP 
regulation imposed by large muscle mass exercise. The results, however, have been 
equivocal. During handgrip exercise, patients with HFrEF have been documented to 
possess both similar (58) as well as attenuated (23, 81) vasodilatory and hyperemic 
responses in the exercising limb, differences which have been attributed to lack of 
standardization with respect to exercise cadence and intensity (35, 58, 69, 76, 81). In 
studies which utilized the single-leg KE exercise model, similar increases in leg vascular 
conductance and leg blood flow have been reported between HFrEF and healthy 
individuals across a range of exercise intensities (15, 33). However, since these studies 
were performed, the clinical treatment of HFrEF has evolved, with the inclusion of new 
pharmacological interventions (18, 21, 31, 66) which might indirectly alter vasomotor 
regulation in response to small muscle mass exercise. Understanding the peripheral 
vasomotor response to small muscle mass exercise in the presence of these recently 
implemented pharmacological interventions could enlighten clinicians on how the 
progression of clinical treatment of patients with HFrEF has affected vascular regulation 
during exercise. Thus, the objective of Specific Aim 2 of this dissertation was to utilize 
both arm and leg exercise models to provide a more definitive and comprehensive 
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assessment of the limb vasodilatory and hyperemic response during small muscle mass 
exercise in HFrEF patients on modern, optimized pharmacotherapy.   
Alpha-Adrenergic Receptor Control of Skeletal Muscle Blood  
Flow during Exercise in Heart Failure with  
Reduced Ejection Fraction 
In the periphery, MSNA is expressed though the stimulation of alpha-adrenergic 
receptors, located on the vascular smooth muscle, leading to vasoconstriction. A small 
number of prospective studies using acute alpha-adrenergic receptor agonist and 
antagonist drug administration have provided some insight concerning the expression of 
sympathoexcitation at the end organ in HFrEF. Zelis et al. (81) reported a qualitatively 
greater percent increase in forearm blood flow between HFrEF and control groups 
following intra-arterial infusion of phentolamine (PHEN), a nonselective alpha-
adrenergic receptor antagonist. Similarly, brachial artery infusion of phenylephrine (PE) 
and BHT-933 (selective alpha-1 and alpha-2 agonists, respectively) in HFrEF patients 
and unmatched, healthy controls produced equivalent decreases in forearm blood flow, 
despite a substantially higher plasma NE concentration in the HFrEF patients (24). 
Findings from these previous studies in HFrEF are somewhat difficult to reconcile with 
more recent work in other populations with elevated SNS activity, where a 
downregulation and/or desensitization of alpha-adrenergic receptors is observed in 
response to chronic sympathoexcitation. For example, in the elderly, a population in 
which SNS activity is also elevated (10, 41, 64), Dinenno et al. (14) observed a 
substantially larger increase in leg blood flow to intra-arterial infusion of PHEN in 
healthy, older individuals compared to their younger counterparts. Our group (79)  and 
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others (9, 61) have observed a blunted alpha-adrenergic receptor vasoconstriction in 
response to intra-arterial sympathomimetic infusions, which likely represents a protective 
response to the 200-300% increase in resting SNS activity and augmented endogenous 
contribution of the alpha-adrenergic receptors to vascular tone reported with advancing 
age.  
This lack of adaptation to high SNS activity in HFrEF likely predisposes these 
patients to an exaggerated cardiovascular response to acute sympathoexcitation, such as 
is seen during physical activity. Indeed, in healthy individuals, vascular conductance in 
the vessels perfusing exercising skeletal muscle is optimized in large part by exercise-
induced reductions in alpha-adrenergic receptor sensitivity, a phenomenon termed 
“functional sympatholysis” (50). However, in HFrEF, the disease-related increase in SNS 
activity and sensitivity of alpha-adrenergic receptors may produce a level of 
vasoconstriction in the exercising muscle vasculature that cannot be entirely overcome, 
resulting in a sustained reduction in vascular conductance and blood flow in this cohort. 
Though a growing number of studies from our group (77-79) and others (11-13, 20, 28, 
53, 54, 59, 70) have examined sympatholysis in healthy humans, very little is known 
concerning whether sympathetic vasoconstriction is altered in HF. In humans, early work 
performed by Zelis et al. (81) identified a substantial reduction in blood flow during 
rhythmic handgrip exercise in HFrEF patients, suggesting an “inadequate arteriolar 
vasodilation” that was partially restored when the exercise was repeated in the presence 
of intra-arterial infusion of PHEN. However, this response was not evident in a 
subsequent study using a similar pharmacologic approach during maximal upright 
cycling (72), and thus the evidence implicating sympathetic overactivity and subsequent 
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vasoconstriction of the exercising muscle vasculature of HFrEF patients remains 
equivocal.  
To our knowledge, no previous studies have directly tested whether 
sympatholysis is impaired in HFrEF patients, or determined if the observations 
concerning arm alpha-adrenergic receptor responses can be extended to the vasculature of 
large, locomotory muscle groups. Specific Aim 3 of this dissertation thus sought to close 
this important knowledge gap by examining the role the alpha-adrenergic receptor 
pathway plays in the regulation of peripheral vasomotor tone and blood flow at rest and 
during exercise in HFrEF patients.  
Hypotheses and Specific Aims 
The objective of this dissertation was to systematically examine the hemodynamic 
response to exercise in HFrEF and healthy control subjects of a similar age, and to 
determine the contribution of the metaboreflex and the alpha-adrenergic receptor pathway 
in the regulation of blood flow and vascular conductance in this cohort. Specifically, the 
first study determined how varying levels of metaboreceptor activation alters the ABP 
response in HFrEF patients, and established the degree to which CO and SVC contribute 
to the metaboreflex-induced pressor response. The second study utilized small muscle 
mass exercise in patients with HFrEF to further investigate the limb-specific peripheral 
vasodilatory and hyperemic response to exercise in isolation of central hemodynamic 
limitations. Building on these studies, the third study examined the contribution of the 
alpha-adrenergic receptor pathway as a mechanism responsible for the disease-related 
impairment in exercising muscle blood flow in HFrEF patients.   
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Specific Aim 1  
Further elucidate the ABP response to varying levels of metaboreceptor activation 
and determine the relative contribution of CO and SVC to the metaboreflex response in 
HFrEF and healthy, age-matched controls.  
Hypothesis 1  
HFrEF patients would exhibit similar increases in MAP across all levels of 
metaboreceptor activation compared to healthy controls.  
Hypothesis 2 
HFrEF patients would exhibit a greater dependence on reductions in SVC than 
increases in CO to achieve the metaboreflex-induced pressor response compared to 
healthy controls. 
Hypothesis 3 
HFrEF patients would exhibit greater increases in arterial afterload and attenuated 
increases in functional systolic work in response to metaboreceptor activation compared 
to healthy controls.  
Specific Aim 2   
Investigate limb-specific peripheral hemodynamic responses to exercise in 





Hypothesis 1  
During both static-intermittent handgrip and single-leg KE exercise, patients with 
HFrEF would exhibit an attenuated hyperemic response driven by an impaired 
vasodilatory capacity compared to healthy controls. 
Specific Aim 3  
Determine the degree to which chronically elevated SNA is expressed in the 
peripheral circulation, both at rest and during dynamic exercise, in patients with HFrEF 
and healthy, age-matched controls. 
Hypothesis 1 
a) At rest, vasoconstriction in response to alpha-1-adrenergic receptor agonist 
drug infusion (PE) would reduce leg blood flow to a similar degree in HFrEF patients 
compared to healthy, age-matched controls.  
           b)  At rest, a greater vasodilation in response to alpha-adrenergic receptor 
antagonist drug infusion (PHEN) would contribute to an enhanced hyperemic response in 
HFrEF patients compared to healthy, age-matched controls. 
Hypothesis 2  
a) During exercise, HFrEF patients would exhibit a sustained responsiveness to 
alpha-1-adrenergic receptor agonist drug infusions into the exercising limb, such that 
functional sympatholysis would be reduced in HFrEF patients compared to healthy, age-
matched controls. 
b) During exercise, HFrEF patients would experience a greater vasodilation to 
alpha-adrenergic receptor antagonist drug infusion in the exercising limb, such that 
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sympathetic restraint of exercising limb blood flow would be greater in HFrEF patients 
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METABORECEPTOR ACTIVATION IN HEART FAILURE WITH REDUCED 





















The present study sought to evaluate the metaboreflex in heart failure patients 
with reduced ejection fraction (HFrEF), with an emphasis on the interaction between 
central and peripheral hemodynamics. In 23 HFrEF patients (63 ± 2 yrs) and 15 healthy, 
controls of a similar age (64 ± 3 yrs), we examined mean arterial pressure (MAP), cardiac 
output (CO), systemic vascular conductance (SVC), effective arterial elastance (Ea), and 
stroke work (SW) during metaboreceptor activation elicited by postexercise circulatory 
occlusion following static-intermittent handgrip exercise (15, 30, and 45% of maximal 
voluntary contraction (MVC)). Across workloads, the metaboreflex-induced increase in 
MAP was similar between groups. In controls, this was driven by increases in CO495 
± 155, 564 ± 156, 666 ± 217 ml/min); however, in HFrEF, this change was 
accomplished by reductions in SVC  ± 1.5,  ± 1.9, ± 1.8  
ml/min/mmHg). This contributed to the exaggerated increases in Ea in HFrEF (0.16 ± 
0.05, 0.32 ± 0.07, 0.36 ± 0.07 mmHg/ml) compared to controls (0.03 ± 0.05, 0.08 ± 
0.07, 0.17 ± 0.06 mmHg/ml) which were associated with the attenuated increases in SW 
in this patient group (3,247 ± 1,446 mmHg*ml / mmHg/ml) compared to controls 
(13,853 ± 3,132 mmHg*ml /mmHg/ml). Together, these findings indicate a preserved 
role of the metaboreflex-induced pressor response in HFrEF, but suggest that this 
response is governed by the peripheral circulation in this cohort, a maladaptation that 





Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome which 
is commonly linked to exercise intolerance and capacity (36, 40). While there are many 
contributing factors to the exercise limitations in this patient population, the role of 
skeletal muscle maladaptations has been increasingly recognized, with specific interest 
focused on the muscle metaboreflex. Activation of this reflex pathway is mediated by 
metabolically sensitive group IV afferent fibers (metaboreceptors) originating in skeletal 
muscle, which increase efferent sympathetic nervous system (SNS) activity in an effort to 
augment the perfusion of the exercising skeletal muscle  through increases in arterial 
blood pressure (ABP) (2, 9, 25). Whether the metaboreflex is altered in HFrEF patients 
remains a topic of ongoing debate (22, 28), with evidence for both exaggerated (6, 20, 23, 
34) and similar (26-28, 32, 33) reflex increases in mean arterial blood pressure (MAP) 
during metaboreflex activation. The disparate findings from these studies suggest that 
significant uncertainty remains regarding disease-related changes in the muscle 
metaboreflex in HFrEF patients, as well as the contribution of this reflex in the 
cardiovascular response to exercise. 
Beyond the simple determination of the pressor response, further insight into the 
importance of metaboreceptor activation in patients with HFrEF may be gained by 
considering the relative contributions of changes in central (i.e. cardiac output (CO)) and 
peripheral (i.e. systemic vascular conductance (SVC)) hemodynamics to the increase in 
MAP in this patient group. Interestingly, in the animal model of heart failure (HF), the 
contributions of these factors to the overall metaboreflex-induced pressor response have 
been documented to be solely due to reductions in SVC across exercise intensities (13). 
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This is vastly different than the response observed in healthy animals, where the 
metaboreflex-induced increases in MAP were predominantly due to increases in CO at 
low to moderate intensities (25) and a shift towards a reliance on SVC to increase MAP 
only during high intensity exercise, when the ability to increase CO was compromised 
(4). In humans, only one study to date has examined central and peripheral contributions 
to the metaboreflex in HFrEF. Crisafulli et al. (9) reported a metaboreflex-induced 
increase in MAP which was predominantly driven by an increase in CO in healthy 
individuals and by a reduction in SVC in patients with HFrEF, suggesting a greater role 
of the peripheral vasculature in governing the pressor response. However, this study only 
included one level of metaboreceptor activation, leaving uncertainty regarding the graded 
nature of the response that has been demonstrated in an animal model of HF (13).  
Whether the metaboreflex-mediated increase in MAP is achieved by central or 
peripheral mechanisms may be of particular significance in HFrEF patients due to the 
potential of this reflex to further stress cardiac muscle through substantial increases in 
afterload. Indeed, SVC, a  measure of systemic vascular tone, represents the nonpulsatile 
component of arterial afterload (16, 41), and considering that patients with HFrEF are 
known to be afterload-sensitive (3, 15, 31), this group can experience severe impairments 
in left ventricular systolic function when arterial afterload is increased (15). Thus, while 
the metaboreflex response is typically viewed as an effective way to increase perfusion of 
the exercising muscle via increases in perfusion pressure in healthy individuals, this 
reflex may exacerbate existing ventricular dysfunction in HFrEF patients if a marked 
reduction in SVC is elicited upon metaboreceptor activation.      
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Thus, the purpose of this study was to implement the use of postexercise 
circulatory occlusion (PECO) following static-intermittent handgrip exercise across a 
range of exercise intensities to comprehensively investigate the interaction between 
central and peripheral responses to metaboreceptor activation. We hypothesized that: 1) 
HFrEF patients would exhibit similar increases in MAP across all levels of 
metaboreceptor activation compared to healthy controls, 2) HFrEF patients would exhibit 
a greater dependence on reductions in SVC than increases in CO to achieve the 
metaboreflex-induced pressor response, and 3) HFrEF patients would exhibit a greater 
increase in arterial afterload and an attenuated increase in functional systolic work in 
response to metaboreceptor activation compared to healthy controls.  
Methods 
Subjects 
23 New York Heart Association (NYHA) class II-III HFrEF patients (22 males 
and 1 female) and 15 healthy, control subjects (14 males and 1 female) of a similar age 
were recruited either by word of mouth or in the HF clinics at the University of Utah 
Health Sciences Center and the Salt Lake City VA Medical Center. All control subjects 
were nonsmokers, not taking any prescription medication, and were free of overt 
cardiovascular disease, as indicated by a health history questionnaire. Protocol approval 
and written informed consent were obtained according to University of Utah and Salt 
Lake City Veterans Affairs Medical Center Institutional Review Board requirements. All 
data collection took place at the Utah Vascular Research Laboratory located at the 
Veterans Affairs Salt Lake City Geriatric, Research, Education, and Clinical Center. All 
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studies were performed in a thermoneutral environment, with subjects reporting to the 
laboratory fasted, and not having performed any exercise within 24 hours of the study.  
Handgrip Exercise and Metaboreceptor Activation  
Subjects were instrumented with a Finometer (Finapres Medical Systems, 
Amsterdam, the Netherlands) on the nonexercising arm, a 3-lead ECG (Biopac, Goleta, 
CA, U.S.A.) to measure heart rate, and a pneumatic blood pressure cuff distal to the 
antecubital fossa on the exercising arm to isolate the metaboreflex following exercise. 
Subjects then rested supine for ≈20 minutes. First, baseline measurements were taken 
over the course of 1-minute. Second, maximal voluntary contraction (MVC) was 
established by taking the highest value recorded of three maximal contractions using a 
handgrip dynamometer (TSD121C, Biopac Systems, Goleta, CA). Static-intermittent 
handgrip exercise was performed at three intensities based on each subject’s respective 
MVC (15, 30, and 45% of MVC). The subjects squeezed the dynamometer to the sound 
of a metronome (60 beats/min) and real-time force output was displayed on a computer 
monitor so that subjects could monitor their effort and make corrections when necessary. 
Each bout of handgrip exercise lasted 3 minutes, and was followed by 2 minutes of 
forearm ischemia to isolate the metaboreflex, with measurements taken during the final 
minute. Forearm ischemia was achieved through the inflation of the pneumatic blood 
pressure cuff on the exercising arm to suprasystolic pressures (>250 mmHg) 5 seconds 
before the end of the handgrip exercise. A 5-minute recovery period was given after each 
period of metaboreceptor activation to allow cardiovascular variables to return to resting 
values. If cardiovascular variables did not return to resting values after 5 minutes, 





Stroke volume (SV), heart rate (HR), CO, and ABP were determined 
noninvasively (Finapres Medical Systems BV, Amsterdam, The Netherlands). SV was  
calculated using the Modelflow method which includes age, sex, height, and weight in its 
algorithm (Beatscope version 1.1; Finapres Medical Systems BV, Amsterdam, The 
Netherlands) (5), and has been shown to accurately track SV during a variety of 
experimental protocols including exercise (10, 11, 35, 38). Pulse pressure (PP), a measure 
of pulsatile load, the nonresistive oscillatory component of arterial afterload (7, 18), was 
calculated as:  
PP (mmHg) = systolic arterial pressure (SAP) – diastolic arterial pressure (DAP) 
Total arterial compliance (TAC), an index of pulsatile arterial afterload which takes into 
account the effect of SV (7, 29), was calculated as:  
TAC (ml/mmHg) = SV/PP 
MAP was calculated as:  
MAP (mmHg) = DAP + (PP*0.33) 
End systolic arterial pressure (Pes) was calculated as (18):  
Pes = 0.9*SAP.  
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CO was calculated as:  
CO (L/min) = SV*HR 
SVC, a measure of systemic vascular tone and the nonpulsatile (mean resistive) 
component of arterial afterload (16), was calculated as:  
SVC (ml/min/mmHg) = CO/MAP 
Systemic vascular resistance (SVR) was calculated as:  
SVR (mmHg/L/min) = MAP/CO 
Effective arterial elastance (Ea), an index of total arterial afterload (both pulsatile and 
nonpulsatile arterial afterload) (18, 29), was calculated as:  
Ea (mmHg/ml) = Pes/SV 
Stroke work (SW), a measure of functional systolic work performed by the left ventricle 
(16, 37), was calculated as:  
SW (mmHg*ml) = Pes*SV 
Rate pressure product (RPP), an index of myocardial oxygen consumption (19), was 
calculated as:  
RPP (AU) = SAP*HR 
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Near infrared spectroscopy   
To determine muscle microvascular deoxyhemoglobin (12) of one specific muscle 
group during exercise and metaboreceptor activation, in a subset of subjects (HFrEF = 
13; control = 9), near infrared spectroscopy (NIRS) was employed on the belly of the 
brachioradialis and the flexor carpi radialis. A frequency-domain multidistance NIRS 
system was utilized (Oxiplex TS, ISS, Champaign, IL) that allows the absolute 
quantification of deoxyhemoglobin concentrations, expressed in µM (14). Prior to use, 
the probe was calibrated using a block with known absorption characteristics to calculate 
the absorption and scattering coefficients. Prior to placement, the skin covering the 
brachioradialis and the flexor carpi radialis was cleaned and double-sided adhesive tape 
was used to seat the diode, which was covered and further secured with coban (3M, St. 
Paul, MN). The data were acquired at 0.5 Hz, and 1-minute averages were calculated 
during the last minute of each exercise bout and during the final minute of PECO.  
Data Analysis 
Statistics were performed using commercially available software (SigmaStat 3.10; 
Systat Software, Point Richmond, CA). For both the exercise and metaboreceptor 
activation portion of the protocol, 2x4 repeated measures ANOVA (α < 0.05) (group: 2 
levels; controls vs. HFrEF) (workload or metaboreflex activation: 4 levels; rest, 15, 30, 
and 45% of MVC) were utilized to determine the exercise and metaboreflex-induced 
alterations in hemodynamic measurements. The Holm-Sidak method was used for alpha 
adjustment and post hoc analysis. Linear regression analysis was performed on individual 
data, with the slope and y-intercept determined to evaluate the associations between the 
metaboreflex-induced changes in SW with Ea and RPP. Student t-tests were used to 
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compare the effect of metaboreflex-induced changes on slope and y-intercept values.  All 
group data are expressed as means ± SEM. 
Results 
Subject Characteristics  
Baseline characteristics of the control subjects and HFrEF patients are displayed 
in Table 2.1. Disease-specific characteristics and medications of patients with HFrEF are 
presented in Table 2.2.   
Rest and Exercise Hemodynamics  
At rest, there were no significant differences in deoxyhemoglobin, MAP, CO, or 
SVC in HFrEF patients compared to controls (Table 2.3). Exercise elicited similar 
intensity-dependent increases in deoxyhemoglobin and MAP between groups (Table 
2.3). The changes in MAP were solely driven by increases in CO across workloads in 
control subjects (Table 2.3) and reductions in SVC in HFrEF patients (Table 2.3). This 
was complemented by substantially attenuated increases in SAP and exaggerated 
increases in DAP in HFrEF compared to control subjects (Table 2.3). These differences 
resulted in a lower PP across exercise intensities in HFrEF, compared to controls (Table 
2.3). However, when factoring in the differences in SV on PP as expressed by TAC, there 
were significant intensity-dependent reductions in TAC observed in control subjects and 
only a significant reduction at the high workload in HFrEF. Additionally, there were no 
significant differences in TAC between groups at any workload (Table 2.3). Ea was 
significantly increased across all workloads in both groups; however, the increases were 
significantly greater in HFrEF patients compared to controls at the two highest workloads 
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(Table 2.3). SW increased significantly across all workloads in the control subjects, with 
no significant difference from rest demonstrated by the HFrEF patients (Table 2.3). This 
was in light of similar RPP’s across all workloads in both groups (Table 2.3).   
Metaboreflex-Induced Changes in Hemodynamics   
Metaboreceptor activation provoked similar increases in tissue deoxyhemoglobin 
(Table 2.4) and MAP (Figure 2.1, top and Table 2.4) across increasing levels of  
metaboreceptor activation between groups. However, the metaboreflex-induced increases 
in MAP were due exclusively to increases in CO in the control group (Figure 2.1, 
middle and Table 2.4), and reductions in SVC in HFrEF (Figure 2.1, bottom and 
Table 2.4).  Similar to exercise, HFrEF patients exhibited a blunted increase in SAP 
across increasing levels of metaboreceptor activation and exaggerated increases in DAP 
compared to controls (Table 2.4). This led to a significantly attenuated increase PP in the 
HFrEF patients, who only established an increase in PP at the highest level of 
metaboreceptor activation (Figure 2.2, top and Table 2.4). However, when factoring in 
the significantly greater increases in SV induced by the metaboreflex exhibited by the 
control subjects compared to HFrEF patients (expressed as TAC), TAC was not 
significantly different between groups at any level of metaboreceptor activation (Figure 
2.2, bottom and Table 2.4). Metaboreceptor activation provoked minimal increases in 
Ea in the control group, who only exhibited a significant increase at the highest level 
(Figure 2.3 and Table 2.4). In contrast, HFrEF patients displayed a significant increase 
in Ea across all levels of metaboreceptor activation and were significantly different from 
control subjects at the highest two levels (Figure 2.3 and Table 2.4). SW was 
significantly increased by metaboreceptor activation at every level of activation in the 
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control group, and only at the highest level in HFrEF patients (Figure 2.4, top and Table 
2.4). This contributed to the significantly lower SW across all levels of metaborceptor 
activation in HFrEF compared to controls (Figure 2.4, top and Table 2.4). These 
differences in SW between groups were due to  significantly blunted changes in Pes 
(Figure 2.4, middle) and SV (Figure 2.4, bottom and Table 2.4), induced by 
metaboreceptor activation in HFrEF patients compared to the control group. Across all 
levels of metaboreceptor activation, similar increases in RPP were observed between both 
groups (Table 2.4).  The slope and the y-intercept of the relationships between 
metaboreflex-induced changes in SW and Ea were significantly greater in the control 
group compared to HFrEF (Figure 2.5). This demonstrates that for a given metaboreflex-
induced change in Ea, there was less of a metaboreflex-induced increase in SW in HFrEF 
compared to the control group. The slope of the relationship between the metaboreflex-
induced changes in SW and RPP were not significantly different between groups (Figure 
2.6). However, the y-intercept was less in the HFrEF group compared to controls (Figure 
2.6), representing a downward shift in the relationship. This indicates that for a given 
metboreflex-induced change in RPP, there was less of a metaboreflex-induced increase in 
SW in HFrEF compared to the control group.  
Discussion 
The present study sought to comprehensively evaluate the muscle metaboreflex in 
HFrEF patients and healthy control subjects of a similar age, with an emphasis on 
investigating the central and peripheral hemodynamic contributions to the metaboreflex-
induced pressor response. Across multiple levels of metaboreceptor activation, the 
increase in MAP was similar between groups, providing new evidence against a disease-
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related exaggeration of the muscle metaboreflex-induced pressor response in HFrEF. 
However, a discrete pattern of central and peripheral hemodynamic changes was 
observed between groups. In control subjects, the pressor response induced by 
metaboreceptor activation was driven by increases in CO, with no significant changes in 
SVC. In contrast, progressively greater reductions in SVC contributed to the pressor 
response in HFrEF patients, while CO remained unchanged. This metaboreflex-induced 
reduction in SVC in HFrEF patients contributed to the reduction in Ea, which was 
associated with a blunted increase in the metaboreflex-induced changes in SW. 
Additionally, a downward shift in the relationship between the metaboreflex-induced 
changes in SW and RPP was observed in HFrE patients compared to control subjects, 
indicating a likely reduction in myocardial efficiency during metaboreceptor activation. 
Together, these findings indicate a preserved role of the muscle metaboreflex-induced 
pressor response in HFrEF. However, the shift to increases in peripheral vasoconstriction 
driving this response in HFrEF patients represents a maladaptive process which places a 
substantial hemodynamic load on the heart, potentially exacerbating the underlying 
impairment in systolic function and myocardial efficiency, and thereby contributing to 
the exercise limitations present in this patient group.   
Metaboreflex Contribution to the Exercise-Induced Changes  
in Mean Arterial Pressure   
It is well-established that patients with HFrEF suffer from a nearly 
insurmountable intolerance to physical exertion (36, 40), which may be due, at least in 
part, to maladaptations in skeletal muscle. Indeed, Drs. Coats and Piepoli have 
hypothesized that abnormalities in sensory reflex activity in skeletal muscle may 
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contribute to the exercise limitations in HFrEF (8, 27), the so-called “muscle hypothesis” 
of HF. Located within the skeletal muscle are two distinct sensory afferent fiber types; 
group III afferent fibers which are predominately mechanically sensitive 
(mechanoreceptors) and group IV afferent fibers (metaboreceptors) which are principally 
sensitive to metabolites produced during exercise (17). Collectively, these reflex 
pathways serve to increase SNS activity, which ultimately increase perfusion pressure (2, 
9, 25). In HF patients, some aspect of this reflex response appears to be dysfunctional.  
While difficult to completely isolate these respective reflex pathways, PECO has 
become a widely adopted approach whereby metabolic byproducts produced during 
exercise are trapped distal to the point of occlusion, thereby activating group IV afferent 
fibers with minimal input from group III fibers (1). Despite extensive use of this 
experimental technique over the past 80 years in both healthy humans and patient 
populations, the exact role of metaboreceptor activation in the cardiovascular response to 
exercise in HFrEF remains a topic of ongoing debate. Indeed, studies which have 
investigated the pressor response during PECO have documented both exaggerated (27, 
32) and similar (6, 20, 23, 34) increases in MAP in HFrEF patients compared to healthy 
individuals. The conflicting findings from these studies indicate that significant 
uncertainty remains as to whether the metaboreflex-induced pressor response is altered in 
HFrEF.  
In the present study, we employed the PECO technique following three different 
handgrip exercise intensities in an effort to comprehensively evaluate the muscle 
metaboreflex in HFrEF patients compared to healthy control subjects of a similar age. As 
displayed in Figure 2.1 (top), we observed a metaboreflex-induced pressor response that 
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was almost identical between groups across all levels of metaboreceptor activation. These 
results are in disagreement with some of the earliest work on the topic (27, 32), and may 
be explained by differences in experimental protocols, including differing handgrip 
exercise paradigms and methods of activating the muscle metaboreflex (PECO vs. limb 
positive pressure). To our knowledge, this is the first study to perform PECO following 
multiple intensities of static-intermittent handgrip exercise, providing a systematic 
assessment of the pressor response across multiple levels of metaboreceptor activation. 
The present findings thus extend on the observations from previous work (6, 20, 23, 34), 
providing new evidence against a disease-related exaggeration of the pressor response 
induced by the muscle metaboreflex in HFrEF patients. 
Central and Peripheral Hemodynamic Contributions to  
Metaboreflex-Induced Changes in  
Mean Arterial Pressure 
While a large breadth of research has focused on elucidating the strength of the 
metaboreflex-induced pressor response in HFrEF, limited work has been undertaken to 
examine variables contributing to this rise in MAP. In a healthy animal model, O’Leary 
et al. (25) documented that the rise in MAP triggered by metaboreceptor activation was 
solely due to increases in CO during low to moderate exercise intensities. Subsequent 
work from the same group reported that the metaboreflex-induced increases in MAP in 
an animal model of HF were primarily due to reductions in SVC (13), indicating that the 
pressor response was achieved exclusively via peripheral vasoconstriction. Based on 
these findings, the authors concluded that the inability of the metaboreflex to increase CO 
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in HF is detrimental as a reduction in SVC is the sole variable this reflex pathway can 
alter in order to increase ABP and ultimately blood flow to exercising skeletal muscle.  
The present study extends these previous findings in animals to human HF, 
documenting metaboreflex-induced increases in MAP in patients with HFrEF (Figure 
2.1, top) that were primarily accomplished through reductions in SVC (Figure 2.1, 
bottom), with virtually no changes in CO (Figure 2.1, middle). This was in marked 
contrast to the response observed in healthy control subjects, where increases in CO 
played a dominant role in increasing MAP during metaboreceptor activation (Figure 2.1, 
middle). To our knowledge, only one other study in humans has examined the roles of 
CO and SVC in increasing MAP during metaboreceptor activation in patients with 
HFrEF. Crisafulli et al. (9) reported a metaboreflex-induced increase in MAP which was 
predominantly driven by an increase in CO in healthy individuals and by a reduction in 
SVC in patients with HFrEF, suggesting a greater role of the peripheral vasculature in 
governing the metaboreflex-induced pressor response in the patient group. However, this 
previous study only investigated the hemodynamic alterations induced by one level of 
metaboreceptor activation, which somewhat limits interpretation. The importance of 
examining multiple levels of metaboreceptor activation should not be underestimated; in 
the animal model, both CO and SVC responses to metaboreceptor activation differed 
significantly with increasing exercise intensity (4, 25). The present study thus provides 
the first comprehensive investigation into the role of CO and SVC in the metaboreflex-
induced pressor response in HFrEF in humans, identifying an intensity-dependent 
reduction in SVC during metaboreflex activation in HFrEF, and thus indicating a 
proportionally greater role of SVC in increasing MAP in this patient group. 
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Arterial Afterload and Systolic Function   
The manner by which metaboreceptor activation elicits an increase in MAP may 
be particularly significant when considering the relationship between the heart and the 
peripheral vasculature in HFrEF patients. Indeed, SVC represents the nonpulsatile 
component of arterial afterload (16, 41) and it is well-established that patients with 
HFrEF are afterload-sensitive (3, 15, 31) and face certain impairment in left ventricular 
systolic function if arterial afterload is increased (15). In the present study, at all levels of 
metaboreceptor activation, HFrEF patients exhibited an exaggerated increase in Ea, an 
index of total arterial afterload, compared to control subjects who only exhibited a 
significant augmentation in Ea at the highest level of metaboreceptor activation (Figure 
2.3). Due to the lack of differences between groups in the reduction in TAC, a measure of 
the pulsatile component of arterial afterload (Figure 2.2, bottom), SVC likely is the 
primary contributor to the exaggerated increase in Ea and total arterial afterload induced 
by metaboreceptor activation exhibited in HFrEF. To our knowledge, this is the first 
study to definitively document an augmented arterial afterload induced by the 
metaboreflex-driven changes in SVC in HFrEF. 
 This metaboreflex-induced increase in arterial afterload in HFrEF appears to have 
deleterious cardiac effects. In HFrEF patients, metaboreceptor activation provoked much 
smaller increases in SW (a measure of functional systolic work) compared to healthy 
control subjects (Figure 2.4, top), and it appears that arterial afterload may have 
contributed significantly to this response. Indeed, the attenuated slope and the downward 
shift in the relationship between  metaboreflex-induced changes in SW, with the reflex 
changes in Ea (Figure 2.5), indicates a marked role of arterial afterload as a primary 
40 
 
restraining factor to the ability of the metaboreflex to increase CO and ultimately 
perfusion pressure in HFrEF. Compounded with these impairments in systolic function, 
HFrEF patients exhibited a reduction in myocardial efficiency, as estimated by the 
downward shift in the relationship between SW and RPP in HFrEF compared to control 
subjects (Figure 2.6). Taken together, these cardiac indices suggest that the 
metaboreflex-induced reductions in SVC and associated increases in afterload come at a 
steep cost to HFrEF patients, comprised of both reductions in systolic work and 
myocardial efficiency.   
Experimental Considerations  
The PECO technique is based on the principle that metabolites produced by the 
exercising skeletal muscle become trapped during circulatory occlusion, maintaining 
activation of the muscle metaboreflex. Though this well-established experimental 
approach provides a reproducible, intensity-dependent pressor response (Figure 2.1), we 
recognize the possibility that the metabolic milieu in the occluded tissue may differ 
between groups. However, this concern is somewhat mitigated by the inclusion of NIRS 
measurements of the occluded muscle, which indicated a similar level of muscle ischemia 
(as quantified by changes in deoxyhemoglobin) between HFrEF and control groups 
during all levels of metaboreceptor activation (Table 2.4). Additionally, we acknowledge 
that the arterial afterload calculations used in the current study are typically based on 
ABP measurements taken centrally, at the aorta (18). Due to the invasive nature and 
feasibility of collecting central aortic pressures in a large cohort of subjects, in the current 
study, ABP measurements were obtained noninvasively via finger 
photoplethysmography. Peripheral ABP measurements are often thought to not 
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completely describe central ABP due to the documented ABP wave amplification 
descending the arterial tree (30, 39). However, central ABP may also be augmented due 
to reflected pressure waveforms (30), therefore limiting the discrepancy in central and 
peripheral ABP. Indeed, prior studies suggest that Pes, when calculated using ABP 
measured peripherally, closely approximates central Pes, overestimating central Pes by less 
than 5% (18, 21, 24).  
Conclusions   
We have identified a preserved role of the metaboreflex-induced pressor response 
in HFrEF patients, and provide evidence that the rise in MAP is governed almost entirely 
by the peripheral circulation in this cohort. The net effect of this response appears to be 
maladaptive, as it places a substantial hemodynamic load on the heart, exacerbates the 
underlying impairment of systolic function, and likely contributes to exercise intolerance 
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Figure 2.1 Metaboreflex-induced changes in mean arterial pressure (top), cardiac output 
(middle), and systemic vascular conductance (bottom) in control subjects and heart failure 
patients with reduced ejection fraction (HFrEF). * Significant difference from control, 
























































































































































































Figure 2.2 Metaboreflex-induced changes in pulse pressure (top) and total arterial 
compliance (bottom) in control subjects and heart failure patients with reduced ejection 
fraction (HFrEF). * Significant difference from control, P<0.05; † Significant difference 










































































































































Figure 2.3 Metaboreflex-induced changes in effective arterial elastance in control 
subjects and heart failure patients with reduced ejection fraction (HFrEF). * Significant 
























































































Figure 2.4 Metaboreflex-induced changes in stroke work (top), end systolic pressure 
(middle), and stroke volume (bottom) in control subjects and heart failure patients with 
reduced ejection fraction (HFrEF). * Significant difference from control, P<0.05; † 

































































































































































Figure 2.5 Relationship between metaboreflex-induced changes in stroke work and 
changes in effective arterial elastance in control subjects and heart failure patients with 
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m = 13853 ± 3132
c = 1885 ± 463
HFrEF
m = 3247 ± 1446*


























Figure 2.6 Relationship between metaboreflex-induced changes in stroke work and 
changes in rate pressure product in control subjects and heart failure patients with 
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m = 1.97 ± 0.45
c = 505 ± 460
HFrEF
m = 1.12 ± 0.43
































Table 2.1 Subject characteristics 
   Control (n = 15)    HFrEF (n = 23 ) 
Age, yrs 64 ± 3 63 ± 2 
Height, cm 176 ± 2 175 ± 1 
Weight, kg 80 ± 4 85 ± 4 
Body mass index, kg/m2 26 ± 1 28 ± 1 
Maximum voluntary contraction, kg 27 ± 2 25 ± 2 
Glucose, mg/dl 85 ± 6 99 ± 4 
Total cholesterol, mg/dl 192 ± 14 155 ± 11 
Triglycerides, mg/dl 143 ± 28 131 ± 12 
HDL, mg/dl 49 ± 4 39 ± 2* 
LDL, mg/dl  124 ± 11 96 ± 8 
HFrEF, heart failure with reduced ejection fraction; HDL, high density lipoprotein; 
LDL, low density lipoprotein. Data are expressed as means ± SEM. * Significant 
difference from control, P <0.05. 
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Table 2.2 Disease - specific characteristics and medications  
   HFrEF (n = 23) 
    
Disease-specific characteristics  
Left ventricular ejection fraction, % (means ± SEM)   22 ± 3 
Diagnosis (ischemic) 14 / 23 
Diagnosis (nonischemic) 9 / 23 
NYHA class II 16 / 23 
NYHA class III 7 / 23 
Diabetic  4 / 23 
    
Medications  
-Blocker 23 / 23 
ACE inhibitor 17 / 23 
Angiotensin receptor inhibitor  4 / 23 
Statin  18 / 23 
Diuretic 18 / 23 
Aldosterone inhibitor    4 / 23 
Calcium channel inhibitor    1 / 23 
Digoxin   4 / 23 
Anticoagulant    13 / 23 
Antiarrhythmic    1 / 23 
Erythropoiesis - stimulating agent  1 / 23 
HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart 




















Table 2.3 Central and peripheral hemodynamics at rest and during exercise   
Workload (%MVC)     Rest 15% 30% 45% 
Control 
Mean arterial pressure, mmHg 83 ± 2 92 ± 2† 96 ± 3† 103 ± 2† 
Systolic arterial  pressure, mmHg 119 ± 3 140 ± 4† 143 ± 5† 154 ± 3 
Diastolic arterial pressure, mmHg 66 ± 2 68 ± 2 73 ± 2† 77 ± 2† 
Pulse pressure, mmHg 53 ± 3 71 ± 4† 70 ± 4† 77 ± 3† 
Heart rate, beats/min 57 ± 2 64 ± 2† 65 ± 2† 68 ± 3† 
Stroke volume, ml/beat   109 ± 5 110 ± 5 111 ± 4 110 ± 4 
Cardiac output, L/min 6.3 ± 0.3 7.0 ± 0.4† 7.2 ± 0.4† 7.4 ± 0.4† 
Systemic vascular conductance, ml/min/mmHg 75 ± 4 77 ± 5 75 ± 4 72 ± 4 
Systemic vascular resistance, mmHg/L/min 14 ± 1 14 ± 1 14 ± 1 14 ± 1 
Total arterial compliance, ml/mmHg  2.2 ± 0.2 1.6 ± 0.1† 1.7 ± 0.2† 1.5 ± 0.1† 
Effective arterial elastance, mmHg/ml 1.0 ± 0.0 1.2 ± 0.0† 1.2 ± 0.1†  1.3 ± 0.1† 
Stroke work, mmHg*ml 11,700 ± 592 13,920 ± 813† 14,357 ± 837†  15,308 ± 683† 
Rate pressure product, AU 6,821 ± 254 8,924 ± 339† 9,354 ± 513† 10,417 ± 440† 
Deoxyhemoglobin, µM (n=9) 27 ± 3 34 ± 4† 37 ± 6† 39 ± 5† 
       HFrEF 
Mean arterial pressure, mmHg 84 ± 3 93 ± 3† 95 ± 4† 102 ± 3† 
Systolic arterial pressure, mmHg 117 ± 4 128 ± 5† 131 ± 5† 141 ± 5*† 
Diastolic arterial pressure, mmHg 67 ± 3 75 ± 3†  77 ± 3 † 83 ± 3† 
Pulse pressure, mmHg 50 ± 3  53 ± 3* 53 ± 4* 58 ± 4*† 
Heart rate, beats/min 67 ± 2* 69 ± 3†  71 ± 2† 73 ± 3† 
Stroke volume, ml/beat   83 ± 4* 81 ± 4* 79 ± 4* 76 ± 4* 
Cardiac output, L/min 5.4 ± 0.3 5.5 ± 0.2* 5.6 ± 0.3* 5.4 ± 0.3* 
Systemic vascular conductance, ml/min/mmHg 68 ± 4 62 ± 3*† 61 ± 4*† 55 ± 3*† 
Systemic vascular resistance, mmHg/L/min 17 ± 2 18 ± 2† 20 ± 3*† 21 ± 2*† 
Total arterial compliance, ml/mmHg 1.8 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.4 ± 0.1† 
Effective arterial elastance, mmHg/ml 1.4 ± 0.1 1.6 ± 0.1† 1.6 ± 0.1*† 1.8 ± 0.2*† 
Stroke work, mmHg*ml 8,654 ± 464 9,253 ± 469* 9,192 ± 529*  9,562 ± 646* 
Rate pressure product, AU 7,677 ± 310 8,902 ± 450† 9,215 ± 455†  10,322 ± 578† 
Deoxyhemoglobin, µM (n=13) 28 ± 2 32 ± 2† 35 ± 2† 36 ± 3† 
MVC, maximum voluntary contraction; HFrEF, heart failure with reduced ejection fraction. Data are expressed as means ± SEM. 










Table 2.4 Central and peripheral hemodynamics at rest and during metaboreceptor 
activation  
Metaboreceptor activation     Rest 15% 30% 45% 
Control 
Mean arterial pressure, mmHg 83 ± 2 90 ± 3† 93 ± 3† 100 ± 2† 
Systolic arterial pressure, mmHg 119 ± 3 132 ± 5† 139 ± 5† 150 ± 5† 
Systolic arterial pressure, mmHg - 13 ± 3† 19 ± 3† 34 ± 4† 
Diastolic arterial pressure, mmHg 66 ± 2 69 ± 2† 70 ± 2†  74 ± 1† 
Diastolic arterial pressure, mmHg - 4 ± 1† 4 ± 1† 8 ± 1† 
Pulse pressure, mmHg 53 ± 3 62 ± 3† 68 ± 4† 75 ± 5† 
Heart rate, beats/min  57 ± 2 58 ± 2 59 ± 2 58 ± 2 
Stroke volume, ml/beat  109 ± 5 118 ± 5† 118 ± 5† 118 ± 5† 
Cardiac output, L/min 6.3 ± 0.3 6.8 ± 0.3† 6.9 ± 0.3† 6.8 ± 0.3† 
Systemic vascular conductance, ml/min/mmHg 75 ± 4 76 ± 3 75 ± 3 68 ± 3† 
Systemic vascular resistance, mmHg/L/min 14 ± 1 14 ± 1 14 ± 1 15 ± 1 
Total arterial compliance, ml/mmHg 2.2 ± 0.2 2.0 ± 0.1 1.8 ± 0.2† 1.7 ± 0.2† 
Effective arterial elastance, mmHg/ml 1.0 ± 0.0  1.0 ± 0.1  1.1 ± 0.1  1.2 ± 0.1† 
Stroke work, mmHg*ml 11,700 ± 592 13,921 ± 695† 14,799  ± 896† 15,941 ± 1,008†
Rate pressure product, AU 6,821 ± 254 7,659 ± 427† 8,217 ± 476† 8,680 ± 325† 
Deoxyhemoglobin, µM (n=9) 27 ± 3 48 ± 6† 50 ± 6† 51 ± 6† 
       HFrEF 
Mean arterial pressure, mmHg 84 ± 3 90 ± 3† 94 ± 3† 100 ± 4† 
Systolic arterial pressure, mmHg 117 ± 4 125 ± 5† 129 ± 5† 140 ± 6† 
Systolic arterial pressure, mmHg - 8 ± 2† 12 ± 2*† 23 ± 3*† 
Diastolic arterial pressure, mmHg 67 ± 3  73 ± 3† 77 ± 3† 81 ± 3† 
Diastolic arterial pressure, mmHg - 7 ± 1† 9 ± 1*† 13 ± 1*† 
Pulse pressure, mmHg 50 ± 3  52 ± 4  53 ± 3* 59 ± 4*† 
Heart rate, beats/min 67 ± 2*  68 ± 2* 70 ± 2* 68 ± 2* 
Stroke volume, ml/beat  83 ± 4* 81 ± 4* 77 ± 4* 80 ± 4* 
Cardiac output, L/min 5.4 ± 0.3 5.5 ± 0.2* 5.3 ± 0.3* 5.4 ± 0.3* 
Systemic vascular conductance, ml/min/mmHg 68 ± 4 63 ± 4*† 58 ± 4*† 55 ± 4*† 
Systemic vascular resistance, mmHg/L/min 17 ± 2 18 ± 2† 20 ± 2*† 21 ± 3*† 
Total arterial compliance, ml/mmHg 1.8 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 1.5 ± 0.1† 
Effective arterial elastance, mmHg/ml 1.4 ± 0.1 1.6 ± 0.2*† 1.7 ± 0.2*† 1.7 ± 0.2*† 
Stroke work, mmHg*ml 8,654 ± 464 9,021 ± 472* 8,896 ± 530* 9,982 ± 635*† 
Rate pressure product 7,677 ± 310 8,572 ± 469† 8,990 ± 426† 9,445 ± 477† 
Deoxyhemoglobin, µM (n=13) 28 ± 2 47 ± 4† 50 ± 4† 53 ± 4† 
MVC, maximum voluntary contraction; HFrEF, heart failure with reduced ejection fraction. Data are expressed as means ± 
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To better understand the mechanisms responsible for exercise intolerance in heart 
failure with reduced ejection fraction (HFrEF), the present study sought to evaluate the 
hemodynamic responses to small muscle mass exercise in this cohort. In 25 HFrEF 
patients (64 ± 2 yrs) and 17 healthy control subjects of a similar age (64 ± 2 yrs), mean 
arterial pressure (MAP), cardiac output (CO), and limb blood flow were examined  
during graded static-intermittent handgrip (HG) and dynamic single-leg knee-extensor 
(KE) exercise. During HG exercise, MAP increased similarly between groups. CO 
increased significantly (+1.3 ± 0.3 L/min) in the control group, but remained unchanged 
across workloads in HFrEF patients. At 15% maximum voluntary contraction (MVC), 
forearm blood flow was similar between groups, while HFrEF patients exhibited an 
attenuated increase at the two highest intensities compared to controls, with the greatest 
difference at the highest workload (352 ± 22 vs. 492 ± 48 ml/min, HFrEF vs. control, 
45% MVC). During KE exercise, MAP and CO increased similarly across work rates 
between groups. However, HFrEF patients exhibited a diminished leg hyperemic 
response across all work rates, with the most substantial decrement at the highest 
intensity (1842 ± 64 vs. 2675 ± 81 ml/min, HFrEF vs. control, 15 W). Together, these 
findings indicate a marked attenuation in exercising limb perfusion attributable to 
impairments in peripheral vasodilatory capacity during both arm and leg exercise in 
patients with HFrEF, which likely plays a role in limiting exercise capacity in this patient 









Heart failure with reduced ejection fraction (HFrEF)  is associated with 
debilitating dyspnea and fatigue triggered by exercise, leading to a limited ability to 
perform everyday tasks and an impaired quality of life (52). Although central cardiac 
limitations are the paramount characteristic of HFrEF, impaired cardiac function does not 
fully explain the degree of exercise intolerance and symptom status in this patient 
population (8, 21, 34, 53, 60). This has steered studies focusing on exercise limitations in 
HFrEF towards potentially limiting factors in the periphery, with particular emphasis on 
disease-related changes in the regulation of skeletal muscle blood flow. Initial studies 
examining the hyperemic response to exercise in the skeletal muscle vasculature of 
HFrEF patients and healthy individuals utilized cycle ergometry, a large muscle mass 
exercise paradigm which results in the recruitment of the vast majority of lower limb 
muscle. These studies observed a marked reduction in blood flow, associated with an 
attenuation in leg vascular conductance, in HFrEF patients during exercise compared to 
their healthy counterparts (52, 62-66). However, due to the cardiac limitations associated 
with HFrEF, the engagement of such a large muscle mass during exercise may have 
outstripped cardiac pumping capacity (30), likely contributing to the observed attenuation 
in leg blood flow and vascular conductance in this patient population.   
These initial studies utilizing cycle ergometry led to the recognition that skeletal 
muscle hyperemic and vasodilatory capacity in HFrEF might be better studied by 
utilizing an exercise paradigm employing a smaller muscle mass, in order to control for 
cardiac limitations. In an animal model of heart failure, this was accomplished by 
utilizing an in situ spinotrapezius muscle preparation and investigating capillary red 




muscle contractions (46). Results from this study convincingly displayed an attenuation 
in capillary red blood cell flux in HF animals compared to control animals. In human HF, 
the two most widely incorporated exercise modalities to study the peripheral 
hemodynamic responses to exercise while controlling for confounding cardiac limitations 
are static-intermittent handgrip (HG) and dynamic single-leg knee-extensor (KE) 
exercise. Despite the implementation of these exercise modalities in a small number of 
studies, results have not definitively determined the extent of peripheral hemodynamic 
limitations in this cohort. Indeed, studies using static-intermittent HG exercise have 
documented both similar (50) and blunted (22, 67) hyperemic responses, linked to 
impairments in vasodilation, in HFrEF patients compared to healthy individuals, 
differences likely attributable to the variations in rhythmicity, duration, and intensity of 
the exercise performed. Using the dynamic single-leg KE exercise model, Esposito et al. 
(14) identified an attenuated hyperemia during maximal effort in HFrEF patients, a 
response that was likely due to the significantly lower maximal KE work rate in the 
patient group compared to healthy individuals. In one of the only studies to utilize KE 
exercise at submaximal work rates in HFrEF patients, Magnusson et al. reported similar 
increases in leg blood flow and vascular conductance between HFrEF and healthy 
individuals (30), suggesting that impaired peripheral hemodynamics may not contribute 
to the exercise intolerance in this cohort.  Thus, significant controversy remains regarding 
the HFrEF-associated alteration of peripheral hemodynamics during exercise modalities 
that minimally challenge central hemodynamics.  
It is noteworthy that significant advances in pharmacotherapy have been made 




Indeed, the average HFrEF patient now receives a pharmacologic regimen that includes 
an average of 10 medications, with beta blockers and a host of peripheral vasodilators 
now included as standard of care (45). Thus, while exercise intolerance remains a key 
clinical presentation in HFrEF, uncertainty exists regarding the possible role of impaired 
peripheral hemodynamics in patients who are optimally medicated in this “modern era” 
of differentiated drug treatment.  
Consequently, we sought to systematically examine peripheral responses to small 
muscle mass exercise in optimally medicated HFrEF patients. To comprehensively assess 
the hemodynamic response to small muscle mass exercise in HFrEF patients and healthy 
control subjects of a similar age, we utilized both upper and lower limb exercise 
paradigms across a wide range of intensities. We hypothesized that compared to healthy 
controls, HFrEF patients would exhibit an attenuated hyperemic response driven by an 




A total of 25 New York Heart Association (NYHA) class II-III HFrEF patients 
(24 males and 1 female) and 17 healthy controls (16 males and 1 female) of a similar age 
were recruited to partake in this study either by word of mouth or in the HF clinics at the 
University of Utah and the Salt Lake City VA Medical Center. All control subjects were 
nonsmokers, not taking any prescription medication, and were free of overt 
cardiovascular disease, as indicated by a health history questionnaire. Protocol approval 




Lake City Veterans Affairs Medical Center Institutional Review Board requirements. All 
data collection took place at the Utah Vascular Research Laboratory located at the 
Veterans Affairs Salt Lake City Geriatric, Research, Education, and Clinical Center. All 
studies were performed in a thermoneutral environment, with subjects reporting to the 
laboratory fasted, and not having performed any exercise within 24 hours of the study. 
Subjects reported to the laboratory on a preliminary day to complete health histories, 
physical examinations, and perform a graded single-leg knee-extensor test to determine 
maximal work rate. 
Handgrip Exercise 
Hemodynamic responses to static-intermittent HG exercise were assessed in 15 
control subjects and 23 patients. Subjects rested in the supine position for ≈20 minutes 
prior to the start of data collection with the right arm abducted at 90°. The elbow joint 
was extended at heart level to allow subjects to perform HG exercise. First, maximal 
voluntary contraction (MVC) was established by taking the highest value recorded of 3 
maximal contractions using a handgrip dynamometer (Biopac Systems, Goleta, CA). 
Static-intermittent HG exercise was performed at 3 workloads based on each subject’s 
respective MVC (15, 30, and 45% of MVC). Each exercise level was performed for 3 
minutes to ensure the attainment of steady-state hemodynamics. The subjects squeezed 
the dynamometer to the sound of a metronome at a rate of 1 Hz, and real-time force 
output was displayed to provide visual feedback to the subjects. A 5 minute recovery 





Single-Leg Knee-Extensor Exercise  
 Hemodynamic responses to dynamic single-leg KE exercise were assessed in 16 
controls and 16 patients. The KE paradigm implemented in this study has been described 
in detail previously (3, 4, 7, 26). Briefly, subjects were seated in a semi-recumbent 
position on an adjustable chair with a cycle ergometer (model 828E; Monark Exercise 
AB, Vansbro, Sweden) positioned behind them. Resistance was created by applying 
friction to the flywheel, which was turned by the subject via a metal bar connecting the 
crank arm of the ergometer to a metal boot in which the subject’s foot was placed. 
Subjects exercised for 3 minutes at 4 work rates (0, 5, 10, and 15 W) while maintaining 
60 contractions per minute. A 5 minute recovery period was given between each exercise 
bout. 
Measurements 
Ultrasound Doppler assessments 
Measurements of brachial and common femoral artery blood velocity and vessel 
diameter were performed using a Logiq 7 ultrasound Doppler system (GE Medical 
Systems, Milwaukee, WI) operating in duplex mode. The Logic 7 was equipped with a 
linear array transducer operating at a Doppler frequency of 5 MHz in high-pulsed 
repetition frequency mode (2-25 kHz). All blood velocity measurements were obtained 
with the probe appropriately positioned to maintain an insonation angle of 60º or less. 
The sample volume was maximized according to vessel size and centered within the 
vessel based on real-time ultrasound visualization. Mean velocity values (angle-
corrected, and intensity weighted area under the curve) were automatically calculated 




end diastole (corresponding to an R wave documented by the simultaneous ECG signal; 
Logic 7) using the same transducer at an imaging frequency ranging from 9 to 14 MHz. 
The brachial artery of the right arm was insonated approximately midway between the 
antecubital and axillary regions, medial to the biceps brachii muscle, while the common 
femoral artery was insonated 2–3 cm proximal to the bifurcation of the common femoral 
artery into the superficial and deep branches. Vessel diameter was determined at a 
perpendicular angle along the central axis of the scanned area. Analysis of brachial artery 
diameter was performed using off-line automatic edge-detection brachial analyzer 
software (Medical Imaging Applications, LLC, Coralville, IA), which is described in 
detail elsewhere (39). Ultrasound Doppler measurements were performed continuously, 
with the last 60 seconds of each exercise intensity used for the determination of limb 
blood flow. Using arterial diameter and Vmean, forearm and leg blood flow were 
calculated as:  
Limb blood flow (ml/min) = (Vmean * π (arterial diameter/2)2 * 60) 
 Hemodynamic variables  
Stroke volume (SV), arterial blood pressure (ABP), and heart rate (HR) were 
determined noninvasively. SV was  calculated using the Modelflow method which 
includes age, gender, height, and weight in its algorithm (Beatscope version 1.1; Finapres 
Medical Systems BV, Amsterdam, The Netherlands) (9), and has been documented to 
accurately track SV during a variety of experimental protocols including exercise (12, 13, 




Medical Systems BV, Amsterdam, The Netherlands), and mean arterial pressure (MAP) 
was calculated as: 
 MAP (mmHg) = diastolic arterial pressure + (pulse pressure * 0.33)  
Heart rate was monitored from a standard 3 lead electrocardiogram recorded in 
duplicate on the data acquisition system (Biopac, Goleta, CA) and the Logic 7. Cardiac 
output (CO) was calculated as:  
CO (L/min) = SV * HR 
Systemic vascular conductance (SVC) was calculated as:  
SVC (ml/min/mmHg) = CO / MAP 
Systemic vascular resistance (SVR) was calculated as:  
SVR (mmHg/L/min) = MAP / CO 
Forearm and leg vascular conductance were calculated as:  
Limb vascular conductance (ml/min/mmHg) = blood flow / MAP 
Data Analysis 
Statistics were performed using commercially available software (SigmaStat 3.10; 
Systat Software, Point Richmond, CA). For HG exercise, 2x4 repeated measures 




30, and 45% of MVC) were performed to determine the hemodynamic responses in 
controls and HFrEF during exercise of increasing intensity. For KE, 2x5 repeated 
measures ANOVA (α < 0.05) (group: 2 levels, controls vs. HFrEF) (work rate, 5 levels: 
rest, 0, 5, 10, 15 W) were utilized to determine the hemodynamic responses in age-
matched controls and HFrEF during exercise of increasing intensity. The Holm-Sidak 
method was used for alpha adjustment and post hoc analysis. A Person Product Moment 
Correlation (α < 0.05) was performed to evaluate the association between leg blood flow 
at 15 W and maximum KE work rate.  All group data are expressed as means ± SEM.   
Results 
Subject Characteristics 
Baseline characteristics of the control subjects and HFrEF patients are displayed 
in Table 3.1. Disease-specific characteristics and medications of patients with HFrEF are 
presented in Table 3.2.   
Handgrip Exercise 
During baseline, prior to HG exercise, there were no significant differences in 
resting MAP, forearm blood flow, forearm vascular conductance, brachial artery 
diameter, or CO between groups (Figure 3.1 and Table 3.3). However, resting HR was 
significantly higher and SV significantly lower in HFrEF patients compared to controls 
(Table 3.3).  
In both groups, MAP and HR increased from resting values in an exercise 
intensity-dependent manner, with no difference between groups (Figure 3.1 and Table 




unchanged in the HFrEF patients (Table 3.3). This significant difference in the CO 
response in HFrEF patients appears to be the result of a tendency for decreased SV across 
workloads, though this reduction did not reach statistical significance (Table 3.3). During 
HG exercise, SVC decreased and SVR increased in HFrEF patients, but remained 
unchanged in the control group (Table 3.3).  
At the lowest intensity (15% MVC), forearm blood flow and vascular 
conductance increased to a similar degree between groups; however, at the higher 
workloads (30 and 45% MVC), HFrEF patients exhibited significantly lower forearm 
blood flow (30 and 45% MVC) and vascular conductance (45% MVC) compared to 
controls (Figure 3.1 and Table 3.3).  
Single-Leg Knee-Extensor Exercise   
During the baseline period prior to KE exercise, there were no significant 
differences in any indices of central or peripheral hemodynamics between groups (Figure 
3.2 and Table 3.4). In both groups, MAP and CO increased from resting values in an 
exercise intensity-dependent manner, with no differences between groups (Figure 3. 2 
and Table3. 4). HR also increased in an intensity-dependent manner, with a significantly 
elevated HR in HFrEF patients compared to controls (5, 10, and 15W) (Table 3.4). SV, 
SVC, SVR remained unchanged in both groups across all KE exercise intensities (Table 
3.4).  In contrast to HG exercise, both leg blood flow and leg vascular conductance were 
markedly reduced at all exercise intensities in HFrEF patients compared to controls 
(Figure 3.2 and Table 3.4), with the greatest reduction (25-35%) present at the highest 




leg blood flow at 15 W and the maximum KE work rate in HFrEF which was not 
apparent in the control group (Figure 3.3). 
Discussion 
This study sought to comprehensively evaluate the hemodynamic responses 
induced by limb-specific, small muscle mass exercise across a wide range of exercise 
intensities in HFrEF patients and healthy, age-matched controls. During HG exercise, a 
divergent hemodynamic response was observed across HG intensities in the HFrEF 
group. Specifically, both groups exhibited a similar forearm hyperemic and vasodilatory 
response during lower intensity (15% MVC) HG exercise, but HFrEF patients exhibited a 
15-25% attenuation in forearm blood flow at higher intensities (30 and 45% MVC), due 
to an impaired vasodilatory capacity. During KE exercise, HFrEF patients exhibited a 20-
35% lower leg blood flow and vascular conductance during KE exercise compared to 
control subjects, with the most substantial decrements at the highest exercise intensity (15 
W). Together, these findings indicate that HFrEF patients on modern, optimized 
pharmacotherapy exhibit a severely compromised ability to vasodilate vasculature of both 
the upper and lower limbs, thus restricting perfusion of the exercising skeletal muscle and 
likely limiting exercise capacity in this patient group.  
Regulation of Skeletal Muscle Blood Flow during Exercise in HFrEF  
A hallmark symptom of patients with HFrEF is an impaired exercise tolerance 
and an associated reduction in maximal exercise capacity (16, 40, 60, 65). Interestingly, 
the degree of left ventricular dysfunction does not fully explain the degree of exercise 




possibility that peripheral hemodynamic dysfunction may contribute to exercise 
intolerance. Evidence from previous studies (62-66) indicate a functional role for 
impaired peripheral hemodynamics in limiting exercise capacity in this cohort during 
peak cycling exercise, where an apparent reduction in leg vascular conductance was 
observed in patients with HFrEF compared to healthy individuals, contributing to the 
documented impairment in perfusion. However, the use of a large muscle mass exercise 
paradigm presents limitations in distinguishing abnormalities in peripheral 
hemodynamics in HFrEF. During exercise that recruits a large fraction of total body 
muscle mass, central circulatory factors play an increasingly important role in the 
preservation of MAP (41, 47, 49). Due to impaired left ventricular function during whole 
body exercise, patients with HFrEF largely depend on systemic vasoconstriction (i.e. 
reductions in SVC) in order to maintain MAP (52). This may indicate that the markedly 
lower leg vascular conductance and associated decrement in perfusion of the exercising 
skeletal muscle during cycling exercise might solely be due to the maintenance of MAP 
versus limitations in vasodilatory capacity in this patient group (52, 66). 
 In order to investigate how altering the total amount of muscle recruited during 
exercise might affect the peripheral hemodynamic responses to exercise in this patient 
group, LeJemtel et al. (28) examined the differences in leg blood flow during maximal 
single- and double-legged upright cycling in HFrEF patients and healthy control subjects. 
Interestingly, they observed similar leg blood flow values in the HFrEF patients during 
both single-and double-legged exercise modalities, which they attributed to an impaired 
vasodilator response in the patient group (28). These results were indirectly supported by 




leg cycling to examine the impact of HF on cardiopulmonary reserve. In this study, 
addition of arm exercise while cycling provoked an increase in peak oxygen (O2) 
consumption in severe HF patients, but not in healthy controls, which was interpreted as 
evidence for an inadequate vasodilator response to exercise resulting in impaired O2 
delivery, as the arterial-venous O2 difference is near maximal in HFrEF during maximal 
leg cycling (25).  
While these novel studies were some of the first to investigate the hemodynamic 
response to exercise which recruited differing amounts of muscle mass during all 
combinations of arm and leg cycling, it is likely that some degree of cardiac limitation 
still confound these results. This is even the case during maximum single-legged cycling, 
where Martin et al. (31) has documented that the CO achieved in HFrEF patients is 
similar compared CO values during maximum double-legged cycling in this patient 
group. Thus, in the present study, we employed two limb-specific small muscle mass 
exercise modalities (static-intermittent HG and dynamic single-leg KE exercise) across a 
range of submaximal exercise intensities in order to more thoroughly investigate the 
peripheral hemodynamic response to exercise in HFrEF in isolation of the significant 
confounding effects of CO limitations and MAP regulation imposed by large muscle 
mass exercise. 
Hemodynamic Responses to Handgrip Exercise 
Due to the accessibility and limited cardiorespiratory stress associated with this 
modality, handgrip exercise has been utilized in a number of studies over the past several 
decades to investigate the peripheral hemodynamic response in HFrEF patients. Indeed, 




intermittent handgrip exercise in HFrEF patients compared to control subjects in the early 
1970’s, and documented an impaired exercise hyperemia in this patient group. However, 
it is noteworthy that this study utilized venous plethysmography to measure blood flow 
during the 10 second relaxation phase between 5 second isometric contractions, an 
approach that precludes assessment of the phasic pattern of blood flow associated with 
rhythmic handgrip exercise. Thus, while this seminal work was among the first to 
examine disease-related changes in regional blood flow during small muscle mass 
exercise, the inherent limitations associated with plethysmographic determination of 
blood flow (29, 67) during low-cadence isometric handgrip exercise left some uncertainty 
regarding the true nature of the hyperemic response in this patient group.  
In the current study, we utilized Doppler ultrasound to measure blood flow 
continuously during 1 Hz static-intermittent handgrip exercise of graded intensity in 
HFrEF patients and control subjects of a similar age. Interestingly, the HFrEF patients 
exhibited a divergent hyperemic and vasodilatory response to static-intermittent HG 
exercise. Specifically, we observed comparable changes in forearm blood flow and 
vascular conductance during low intensity (15% MVC) exercise between HFrEF patients 
and healthy controls, and a divergence at higher intensities, with HFrEF patients 
exhibiting an impaired ability to alter vasomotor tone and therefore increase blood flow 
(Figure 3. 1 and Table 3.3). Using a similar HG exercise model and a single, low-
intensity workload (4.4kg, ≈15% MVC), Shoemaker et al. (50) reported a similar 
hemodynamic response in HFrEF patients and controls, suggesting a preserved 
vasomotor regulation and hyperemic response in HFrEF patients when performing HG 




range of exercise intensities (Figure 3.1), this former study did not characterize the full 
scope of the hemodynamic and vasodilatory response in HFrEF. Thus, using beat-to-beat 
measurements, a dynamic (1 Hz) exercise cadence, and a wide range of exercise 
intensities, the  present study both confirms and extends these previous findings, 
unmasking a marked impairment in forearm blood flow that may be attributed to a 
limited limb-specific vasodilatory capacity in the exercising skeletal muscle vasculature 
of HFrEF patients. 
This reduction in forearm blood flow and vascular conductance in HFrEF patients 
was accompanied by a clear lack of an increase in CO across increasing intensities of 
exercise in this patient group (Table 3.3), which is in contrast to the robust (≈1 L/min, 
Table 3.3) increase observed in the control group at the highest exercise intensity. While 
the mechanisms responsible for this physiological adjustment to static-intermittent HG in 
HFrEF are unknown, a potential explanation for the absence of an exercise-induced 
increase in CO is the substantial reduction in SVC exhibited in this patient group (Table 
3.3). Indeed, SVR (the inverse of SVC), is commonly used as a measurement of 
nonpulsatile arterial load on the left ventricle (35, 37, 59) and it is well-established that 
patients with HFrEF are afterload-sensitive (6, 24, 48) and face impairments in left 
ventricular systolic function if arterial afterload is increased (24). However, it is a 
possibility that the unique cardiovascular adjustments associated with HG exercise in 
HFrEF might not elicit a sufficient stimulus to induce an increase in CO, thus requiring a 
reduction SVC in order to increase MAP in this patient group.  Thus, it is tempting to 
speculate that during HG exercise, impaired blood flow within the exercising muscle 




increase in CO in HFrEF patients. The “real world” implications of this response are not 
trivial; indeed, the cardiovascular adjustments observed with this HG exercise modality 
may also be present during tasks of daily living that utilize the upper limbs, such as 
carrying groceries. Thus, the observed impairment in vasodilation and the accompanying 
absence of central responses may be viewed as representing a previously unexplored 
aspect of exercise intolerance that could contribute to the diminished quality of life in this 
patient group.    
Hemodynamic Responses to Single-Leg Knee-Extensor Exercise  
While these data during HG exercise demonstrate a clear impairment in forearm 
hemodynamics, exercise intolerance in HFrEF patients has classically been documented 
during tasks primarily involving locomotion (16, 40, 60, 65), and thus further 
investigating the hemodynamic responses to physical exertion in the skeletal muscle 
vasculature of the legs is also warranted. During single-leg KE exercise, HFrEF patients 
exhibited a persistent impairment in the ability to overcome the tonic vasomotor restraint 
of the lower limb vasculature across increasing exercise intensities (Table 3.4), thus 
limiting perfusion of the exercising limb (Figure 3.2).  These results are in contrast to 
Magnusson et al. (30), one of the only other studies to examine changes leg blood flow 
during submaximal KE exercise in this patient group. In this previous study, similar 
increases in leg blood flow and vascular conductance were observed across graded 
exercise intensities in HFrEF patients compared to controls. Though the reasons for this 
discrepancy between this former study and the present findings are not immediately 
obvious, one likely explanation is the evolution of pharmacotherapy associated with the 




proven efficacious in the treatment of HFrEF since this previous study was undertaken, 
one noteworthy change in pharmacologic standard of care for these patients over the past 
two decades is a reduction in the prevalence of positive inotropes. Indeed, the vast 
majority of patients in the aforementioned study were prescribed digoxin, a drug that has 
been documented to attenuate sympathetic nervous system activity (58), reduce 
circulating norepinephrine (2, 17, 54), and increase peripheral artery vasodilation (32) in 
HFrEF patients. This supports the concept that the higher exercising leg blood flow 
documented by Magnusson et al. might be due to a digoxin-induced release of 
sympathetic restraint on peripheral vascular tone.   
Additionally, there was a strong association between leg blood flow at a given 
absolute work rate (15 W) and the maximum KE work rate achieved in HFrEF patients 
which was not present in the control group (Figure 3.3). This is a unique finding, as 
blood flow is traditionally thought to match the metabolic demand of a given amount of 
work performed (44). Indeed, the current study (Figure 3.3) and previous work (4), have 
documented similar leg blood flow values during KE exercise of a given absolute work 
rate in healthy individuals with varying maximal knee-extensor work rates. This HFrEF-
specific relationship suggests that the more severe the impairment in exercise hyperemia, 
the more substantial the decrements in these patients’ respective capacity to perform 
work.  
In contrast to HG exercise, the exercise-induced changes in CO during KE 
exercise in the present study were remarkably similar between groups (Table 3.4), a 
differing response that is potentially attributed to a preserved SVC during KE exercise in 




of the KE exercise model, a small muscle mass modality that is capable of eliciting large, 
concomitant linear increases in skeletal muscle blood flow and CO without potential 
confounding factors limiting the intensity-dependent increase in CO capacity performed 
at submaximal intensities. Indeed, at the highest exercise intensity (15 W), almost 
identical CO values were observed in HFrEF and control groups, while leg blood flow 
was ≈35% lower in the patient group. Together, these central and peripheral responses 
provide new evidence for a persistent restraint of skeletal muscle blood flow during leg 
exercise in optimally medicated HFrEF patients that cannot be explained by disease-
related impairments in CO, implicating the lower limb peripheral vasculature as a 
significant contributor to the limited exercise capacity displayed by optimally medicated 
patients with HFrEF.  
Perspectives   
It is important to acknowledge that O2 transport during exercise is a multifaceted 
process which includes both the bulk delivery of O2 to the exercising muscle (i.e 
convective O2 transport) via increases in arterial blood flow as well as the local O2 
distribution to the exercising  skeletal muscle via the unloading of O2 from hemoglobin to 
the skeletal muscle mitochondria (i.e. diffusional O2 conductance) (42, 43, 56, 57). While 
the present study convincingly demonstrates an attenuated blood flow response during 
graded exercise in HFrEF patients, likely contributing to an impairment in convective O2 
transport, deficiencies in diffusional conductance might be contributing to a systemic 
impairment in O2 transport in patients with HFrEF during exercise as well. Indeed, 
Esposito et al.(14) demonstrated an attenuated diffusional O2 conductance in HFrEF 




may have been attributable to the significantly lower maximal KE work rate in the patient 
group. Further studies are certainly warranted to investigate whether the impairments in 
diffusional conductance present in HFrEF during maximal exercise extends to 
submaximal exercise intensities. 
It is widely accepted that one of the goals of pharmacotherapy for patients with 
HFrEF has been to relieve symptoms, many of which are associated with physical 
exertion and exercise intolerance (5, 10). While the early historical progression of the 
optimization of pharmacological therapy in HFrEF largely focused on improving left 
ventricular function through the use of positive inotropes (5, 18), the introduction of 
vasodilator therapy in the 1980’s was a therapeutic milestone (5, 10). Indeed, the 
demonstrated beneficial effect of antihypertensive drugs including nitrate-based 
medications (i.e. hydralazine) (11) and angiotensin-converting enzyme (ACE) inhibitors 
(1, 11, 15)  on exercise intolerance and exercise-related symptoms has established 
important pleiotropic properties for these drug classes that are of significant value in the 
treatment of HFrEF. However, based on the findings from the current study, the 
combined effect of vasodilators currently available and widely prescribed in HFrEF (i.e. 
ACE inhibitors, aldosterone receptor antagonists, angiotensin receptor blockers, and 
vasodilating beta-adrenergic antagonists such as carvedilol) might not be sufficient to 
restore peripheral vasodilation during exercise.     
Experimental Considerations  
Several limitations to the present study are worth noting. While skeletal muscle 
vasodilation contributes significantly to the overall regulation of exercise hyperemia, we 




the observed impairment in blood flow during exercise in HFrEF. Indeed, disease-related 
changes in vascular architecture, including capillary rarefaction (36, 61) and impairments 
in vascular flow capacity (33) may contribute to reduced limb blood flow independent of 
disease-related alterations in vascular control. We also recognize that the observed 
reduction in leg blood flow in HFrEF patients in the face of similar CO values between 
groups raises the question of whether blood flow distribution may be disturbed in the 
HFrEF cohort. While the current study cannot answer this question, we acknowledge the 
possibility that increased blood flow to respiratory muscles may be partially responsible 
for our observed results during exercise in HFrEF. Indeed, during cycling exercise, Olson 
et al. (38) documented that HFrEF patients preferentially “steal” blood flow from the 
exercising skeletal muscle in order to accommodate their enhanced work of breathing. 
Additionally, in the present study, calculations of both systemic and regional vascular 
conductance were made using only arterial pressure, rather than the more conventional 
arterial-venous pressure difference. Thus, we cannot exclude the possibility that potential 
changes in venous pressure associated with HFrEF may have confounded our findings. 
However, we have recently reported similar venous pressures during maximal KE 
exercise in HFrEF and control subjects (14), an observation that somewhat mitigates this 
concern. We also acknowledge the lack of a direct assessment of exercise tolerance in the 
HFrEF group, though the observation that leg blood flow at a given absolute work rate 
was strongly associated with the maximum KE work rate in HFrEF patients (and not in 
healthy controls) is a strong indication that impairments in exercise hyperemia 
contributed to the limited work capacity in the patient group. Finally, based on the 




wish to emphasize that a direct comparison of hemodynamic responses between these 
two exercise modalities is not possible.  
Conclusions  
Using a wide range of exercise intensities, we have identified a clear impairment 
in perfusion of both the upper and lower limbs during small muscle mass exercise in 
HFrEF patients. These findings indicate that HFrEF patients on modern, optimized 
pharmacotherapy exhibit a severely compromised peripheral hyperemic response, 
implicating maladaptations in the peripheral vasculature and its regulation as potential 
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Figure 3.1 Forearm blood flow (top) and mean arterial pressure (bottom) at rest and 
during static-intermittent handgrip exercise in control subjects and heart failure patients 
with reduced ejection fraction (HFrEF). * Significant difference from control, P<0.05; † 






























































































Figure 3.2 Leg blood flow (top) and mean arterial pressure (bottom) at rest and during 
dynamic single-leg knee-extensor exercise in control subjects and heart failure patients 
with reduced ejection fraction (HFrEF). * Significant difference from control, P<0.05; † 



































































































Figure 3.3 Relationship between leg blood flow at 15 W and maximal single-leg knee-
extensor work rate in control subjects and heart failure patients with reduced ejection 

























































Single-Leg Knee-Extensor Maximum (W)































Table 3.1 Subject characteristics 
   Control (n = 17 )   HFrEF (n = 25 ) 
Age, yrs 64 ± 2 64 ± 2 
Height, cm 177 ± 2  171 ± 3 
Weight, kg 87 ± 7 85 ± 3 
Body mass index, kg/m2 25 ± 1 28 ± 1 
Systolic blood pressure, mmHg 120 ± 3 117 ± 4 
Diastolic blood pressure, mmHg  70 ± 2 67 ± 3 
Maximum voluntary contraction, kg 27 ± 2 (n = 15) 25 ± 2 (n = 23) 
Knee-extensor maximum, W   35 ± 2 (n = 16)    19 ± 1 (n = 16)* 
Glucose, mg/dl 85 ± 5 99 ± 4* 
Total cholesterol, mg/dl 188 ± 12 151 ± 10* 
Triglycerides, mg/dl 130 ± 24 131 ± 11 
HDL, mg/dl 48 ± 3 38 ± 2* 
LDL, mg/dl  123 ± 9 93 ± 7* 
HFrEF, heart failure with reduced ejection fraction; HDL, high density lipoprotein; 
LDL, low density lipoprotein. Data are expressed as means ± SEM. * Significant 





























Table 3.2 Disease - specific characteristics and medications  
   HFrEF (n = 25) 
    
Disease-specific characteristics  
Left ventricular ejection fraction, % (means ± SEM)   23 ± 2 
Diagnosis (ischemic) 16 / 25 
Diagnosis (nonischemic) 9 / 25 
NYHA class II 18 / 25 
NYHA class III 7 / 25 
Diabetic  5 / 25 
    
Medications  
-Blocker 25 / 25 
ACE inhibitor 19 / 25 
Angiotensin receptor inhibitor  4 / 25 
Statin  20 / 25 
Diuretic 20 / 25 
Aldosterone inhibitor    4 / 25 
Calcium channel inhibitor    1 / 25 
Digoxin   4 / 25 
Anticoagulant    15 / 25 
Antiarrhythmic    1 / 25 
Erythropoiesis - stimulating agent  1 / 25 
HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart 





















Table 3.3 Central and peripheral hemodynamics at rest and during handgrip 
exercise   
Workload (% MVC)     Rest 15% 30% 45% 
     
Control 
Forearm vascular conductance, ml/min/mmHg 1.1 ± 0.2 2.5 ± 0.3† 3.8 ± 0.4† 4.8 ± 0.4† 
Brachial artery diameter (cm) 0.47 ± 0.02 0.48 ± 0.02† 0.51 ± 0.02† 0.52 ± 0.02† 
Brachial artery blood velocity (cm/sec) 9 ± 1 20 ± 1† 30 ± 2† 37 ± 2† 
Heart rate, beats/min 57 ± 2  64 ± 2† 65 ± 2† 68 ± 3† 
Stroke volume, ml/beat 109 ± 5 110 ± 5 111 ± 4 110 ± 4 
Cardiac output, L/min 6.3 ± 0.3 7.0 ± 0.4† 7.2 ± 0.4† 7.4 ± 0.4† 
Systemic vascular conductance, ml/min/mmHg 75 ± 4 77 ± 5 75 ± 4 72 ± 4 
Systemic vascular resistance, mmHg/L/min 14 ± 1 14 ± 1 14 ± 1 14 ± 1 
       HFrEF 
Forearm vascular conductance, ml/min/mmHg 1.1 ± 0.2 2.5 ± 0.2† 3.2 ± 0.3† 3.6 ± 0.3*† 
Brachial artery diameter (cm) 0.47 ± 0.02 0.48 ± 0.02 0.48 ± 0.01† 0.49 ± 0.01† 
Brachial artery blood velocity (cm/sec)  8 ± 1 21 ± 1† 27 ± 1† 31 ± 1*† 
Heart rate, beats/min 67 ± 2* 69 ± 3† 71 ± 2† 73 ± 3† 
Stroke volume, ml/beat 83 ± 4* 81 ± 4* 79 ± 4* 76 ± 4* 
Cardiac output, L/min 5.4 ± 0.3 5.5 ± 0.2* 5.6 ± 0.3* 5.4 ± 0.3* 
Systemic vascular conductance, ml/min/mmHg 68 ± 4 62 ± 3*† 61 ± 4*†  55 ± 3*† 
Systemic vascular resistance, mmHg/L/min 17 ± 2 18 ± 2† 20 ± 3*† 21 ± 2*† 
MVC, maximum voluntary contraction; HFrEF, heart failure with reduced ejection fraction. Data are expressed as 




















Table 3.4 Central and peripheral hemodynamics at rest and during single-leg 
knee-extensor exercise   
Work rate (W)     Rest 0 5 10 15 
Control  
Leg vascular conductance, ml/min/mmHg 3.5 ± 0.3 17.2 ± 0.7† 20.6 ± 0.8† 24.1 ± 0.9† 26.8 ± 1.1† 
Common femoral artery diameter, cm 1.05 ± 0.03 1.05 ± 0.03 1.05 ± 0.03 1.05 ± 0.03 1.05 ± 0.03 
Common femoral artery blood velocity, cm/sec 6 ± 1 32 ± 2† 34 ± 2† 46 ± 3† 53 ± 3† 
Heart rate, beats/min 64 ± 2 72 ± 2† 74 ± 2† 76 ±2†  78 ± 2† 
Stroke volume, ml/beat 88 ± 3 92 ± 4 95 ± 5 93 ± 6 97 ± 4 
Cardiac output, L/min 5.5 ± 0.2 6.6 ± 0.3† 7.0 ± 0.3† 7.0 ± 0.4† 7.5 ± 0.3† 
Systemic vascular conductance, ml/min/mmHg 67 ± 2 71 ± 3 75 ± 4 73 ± 5 75 ± 3 
Systemic vascular resistance, mmHg/L/min 15 ± 1 14 ± 1  14 ± 1 15 ± 1 14 ± 1 
           HFrEF 
Leg vascular conductance, ml/min/mmHg 2.7 ± 0.2 12.6 ± 0.8*† 15.7 ± 0.7*† 17.4 ± 0.8*† 17.6 ± 0.7*† 
Common femoral artery diameter, cm 0.96 ± 0.03* 0.96 ± 0.03* 0.96 ± 0.03* 0.96 ± 0.03* 0.96 ± 0.03* 
Common femoral artery blood velocity, cm/sec 6 ± 1 30 ± 3† 36 ± 3† 41 ± 4† 43 ± 3† 
Heart rate, beats/min 68 ± 2 79 ± 4† 85 ± 5*† 89 ± 5*† 94 ± 4*† 
Stroke volume, ml/beat 82 ± 9 92 ± 12 86 ± 11 83 ± 10 82 ± 10 
Cardiac output, L/min 5.4 ± 0.5 6.8 ± 0.6† 7.0 ± 0.8† 7.0 ± 0.8† 7.3 ± 0.7† 
Systemic vascular conductance, ml/min/mmHg 65 ± 6 70 ± 7 72 ± 8 72 ± 8 69 ± 6 
Systemic vascular resistance, mmHg/L/min 19 ± 3 16 ± 2 18 ± 3 17 ± 2 17 ± 2 
HFrEF, heart failure with reduced ejection fraction. Data are expressed as means ± SEM.* Significant difference from control, 


















ALPHA-ADRENERGIC RECEPTOR REGULATION OF SKELETAL MUSCLE 
BLOOD FLOW DURING EXERCISE IN HEART FAILURE WITH  























Heart failure patients with reduced ejection fraction (HFrEF) experience impaired 
limb blood flow during exercise, which may be due to disease-related changes in alpha-
adrenergic receptor vasoconstriction. Thus, in eight HFrEF patients (63 ± 4 yrs) and eight 
age- and sex-matched controls (63 ± 4 yrs), we examined changes in leg blood flow 
(Doppler ultrasound) during intra-arterial infusion of phenylephrine (PE; alpha-1-
adrenergic receptor agonist) and phentolamine (PHEN; nonspecific alpha-adrenergic 
receptor antagonist) at rest and during dynamic single-leg knee-extensor exercise (0, 5, 
and 10 W). At rest, the reduction in blood flow induced by PE was significantly blunted 
in HFrEF patients (-15 ± 7%) compared to controls (-36 ± 5%). During exercise, the 
control subjects exhibited a blunted reduction in blood flow induced by PE (-12 ± 4, -10 
± 4, -9 ± 2% at 0, 5, and 10 W) compared to rest, while the PE-induced change in blood 
flow was unchanged compared to rest in the HFrEF patients (-8 ± 5, -10 ± 3, -14 ± 3%). 
PHEN administration increased leg blood flow to a greater extent in HFrEF both at rest 
(+178 ± 34% vs. +114 ± 28%, HFrEF vs. control) and during exercise (36 ± 6, 37 ± 7, 39 
± 6% vs. 13 ± 3, 14 ± 1, 8 ± 3% at 0, 5, and 10W,  HFrEF vs. control). Taken together, 
these findings implicate disease-related changes in the alpha-adrenergic receptor pathway 
as an important maladaptive process that restrains exercising skeletal muscle blood flow 








Heart failure with reduced ejection fraction (HFrEF) is associated with 
debilitating dyspnea and fatigue triggered by tasks of everyday living, limiting the ability 
for physical exertion and impairing quality of life (44).  Interestingly, while systolic 
ventricular dysfunction is, by definition, a fundamental characteristic of HFrEF, it does 
not fully explain the degree of exercise capacity or symptom status in this patient 
population (8, 20, 27, 46, 49). In contrast, our group (7) and others (57) have documented 
an attenuated blood flow response to exercising skeletal muscle induced by small muscle 
mass exercise in HFrEF compared to healthy individuals. Considering the lack of 
evidence for alternations in perfusion pressure during exercise in patients with HFrEF 
(30, 39, 44), a blunted rise in vascular conductance is likely the primary contributing 
factor to the apparent attenuation in exercise hyperemia in this cohort.  
 A likely culprit offsetting the rise in vascular conductance during exercise in 
HFrEF is the underlying increase in sympathetic nervous system (SNS) activity in this 
patient population (13, 25, 48). In an effort to examine the end-organ expression of this 
exaggerated sympathoexctation in HFrEF, a small number of studies have investigated 
the effective changes to resting vasomotor tone induced by local intra-arterial infusion of 
alpha-adrenergic receptor agonists and antagonist drugs. At rest, a qualitatively greater 
percent increase in forearm blood flow has been documented in response to brachial 
artery infusion of the nonspecific alpha-adrenergic receptor antagonist phentolamine 
(PHEN) in patients with HFrEF compared to healthy individuals (57). Additionally, 
similar dose-dependent reductions in forearm blood flow were observed in response to 
subsequent administration of phenylephrine (PE) and BHT-993 (selective alpha-1 and 





elevated plasma norepinephrine (NE) (21). Together, these studies indicate a heightened 
contribution from alpha-adrenergic receptor vasoconstriction to forearm vascular tone in 
HFrEF patients, coupled with an apparent lack of desensitization of alpha-adrenergic 
receptors of the forearm vasculature in the presence of chronically heightened 
sympathoexcitation (21).  
These findings at rest raise the question of whether the exaggerated increase in 
SNS activity during physical activity (28, 30, 39, 42), coupled with the preserved alpha-
adrenergic receptor responsiveness (21), could generate a degree of vasoconstriction in 
the exercising skeletal muscle vasculature that could account for the attenuated exercise 
hyperemia in this cohort. Using intra-arterial infusion of PHEN to locally abolish 
sympathetic restraint of skeletal muscle blood flow, Zelis et al. (57) documented that 
alpha-adrenergic receptor-mediated vasoconstriction plays a greater role in restraining 
blood flow during handgrip exercise in HFrEF patients compared to control subjects, 
though this response was not evident in a subsequent study using a similar pharmacologic 
approach during maximal upright cycling (50). However, to our knowledge, the degree to 
which alpha-adrenergic receptor responsiveness is reduced during exercise in order to 
optimize blood flow to exercising skeletal muscle, a phenomenon termed “functional 
sympatholysis” (32), has yet to be determined in patients with HFrEF.   
Thus, the present study sought to further determine the role of alpha-1-adrenergic 
receptor responsiveness, the endogenous contribution alpha-adrenergic receptor pathway 
to vascular tone and the regulation of skeletal muscle blood flow in leg at rest, as well as 
determine if these drug-induced changes in vascular tone and blood flow differ as a 





matched controls. We hypothesized that: 1a) At rest, vasoconstriction in response to 
alpha-1-adrenergic receptor agonist drug infusion (PE) would reduce leg blood flow to a 
similar degree in HFrEF patients compared to age-matched controls, 1b) At rest, a greater 
vasodilation in response to alpha-adrenergic antagonist drug infusion (PHEN) would 
contribute to an enhanced hyperemic response in HFrEF patients compared to age-
matched controls, 2a) During exercise, HFrEF patients would exhibit a sustained 
responsiveness to alpha-1-adrenergic receptor agonist drug infusions into the exercising 
limb, such that functional sympatholysis would be reduced in HFrEF patients compared 
to age-matched controls, and 2b) During exercise, HFrEF patients would experience a 
greater vasodilation to alpha-adrenergic receptor antagonist drug infusion in the 
exercising limb, such that sympathetic restraint of exercising limb blood flow would be 
greater in HFrEF patients compared to age-matched controls. 
Methods 
Subjects 
8 New York Heart Association (NYHA) class II-III HFrEF patients and 8 healthy, 
age- and sex-matched control subjects were recruited either by word of mouth or in the 
HF clinics at the University of Utah Health Sciences Center and the Salt Lake City VA 
Medical Center. All age-matched control subjects were nonsmokers, not taking any 
prescription medication, and were free of overt cardiovascular disease, as indicated by a 
health history questionnaire. Protocol approval and written informed consent were 
obtained according to University of Utah and Salt Lake City Veterans Affairs Medical 
Center Institutional Review Board requirements. All data collection took place at the 





Geriatric, Research, Education, and Clinical Center. All studies were performed in a 
thermoneutral environment, with subjects reporting to the laboratory fasted, and not 
having performed any exercise within 24 hours of the study. Subjects reported to the 
laboratory on a preliminary day to complete health histories, physical examinations, and 
perform a graded single-leg knee-extensor (KE) test to determine maximal work rate. 
Subjects reported to the UVRL at 0800 on the experimental day. After 20 minutes 
of supine rest, two catheters (common femoral artery (CFA) and vein (CFV)) were placed 
using sterile technique, as described previously (2, 5, 6, 56). After catheter placement, 
subjects rested for ≈30 minutes, and then undertook the protocol as outlined in Figure 
4.1. Subjects were given a small, standardized meal (1/2 cup of corn flakes and 1/2 cup of 
skim milk) 5 minutes prior to the start of the exercise portion the alpha-1-adrenergic 
receptor agonist (PE) trial (Figure 4.1A) and the nonspecific alpha-adrenergic receptor 
antagonist (PHEN) trial (Figure 4.1B). We have previously reported that this meal does 
not affect leg blood flow at rest or during exercise (6). All data collection took place with 
subjects in a semirecumbent position (60° reclined). Due to the long lasting effects of 
PHEN, this portion of the protocol always occurred after the PE portion. Additionally, 
during both parts of the study, a nonspecific beta-adrenergic receptor antagonist 
(propranolol) was administered to the healthy control subjects to minimize confounding 
effects of beta-adrenergic receptor stimulation (Figure 4.1). Propranolol was not 
administered in the HFrEF patients due to the presence of nonspecific beta-adrenergic 








Thigh volumes were determined anthropometrically, and then used for the 
calculation of drug dosing (23). 
Beta-adrenergic receptor antagonist  
 Propranolol Hydrochloride (APP Pharmaceuticals LLC, Schaumburg, IL) was 
administered as the nonselective beta-adrenergic receptor antagonist. Propranolol was 
prepared at a concentration of 0.5 mg/ml in 0.9% sterile saline and 10 ml (5 mg of 
propranolol) was administered intravenously over the course of 30 seconds before the 
beginning of both the PE and PHEN protocols (Figure 4.1). This dose has been 
documented to block beta-adrenergic receptors in the peripheral circulation, ablating the 
forearm vasodilation response to infusion of epinephrine (Epi) (22).  
Alpha-1-adrenergic receptor agonist 
Phenylephrine (PE) (Sigma-Aldrich, St. Louis, MO) was administered as a 
selective alpha-1-adrenergic receptor agonist. PE was prepared at a concentration of 2.5 
μg/ml of 0.9% sterile saline. At rest, PE was infused intra-arterially at five doses (0.015, 
0.03, 0.06, 0.12, 0.24 µg/min/dl thigh volume, 2 minutes per dose) using a constant-speed 
infusion pump (Harvard Apparatus, Holliston, MA). During exercise, real-time blood 
flow was determined prior to PE infusion using ultrasound Doppler, and infusion rate was 
blood flow adjusted according to these “on-the-fly” blood flow values, to ensure similar 
effective concentration of the drug at rest and during exercise (Figure 4.1A). This flow-
adjusted dose was similar to the 0.12 µg/min/dl thigh volume dose of PE administered at 





vasoconstriction, while limiting the risk of systemic spillover during the high infusion 
rates that occur during single-leg KE  exercise  (52).   
Nonspecific alpha-adrenergic receptor antagonist 
Phentolamine Mesylate (PHEN) (Regitine, Bedford Labs, Bedford, OH) was 
administered as the nonselective alpha-adrenergic receptor antagonist. PHEN was 
prepared at a concentration of 0.3 mg/ml in 0.9% sterile saline and infused intra-arterially 
for 10 minutes (total dose: 2.25 mg) (Figure 4.1B), followed by a maintenance dose (300 
µg/min) for the remainder of the protocol. This dose exceeds that which has been 
previously documented to achieve complete alpha-adrenergic receptor blockade, as 
confirmed by alpha-adrenergic receptor agonist challenge (17).   
Single-Leg Knee-Extensor Exercise  
The single-leg KE paradigm which was implemented in this study has been 
described previously (3, 4, 6, 24, 33, 55). Briefly, subjects were seated in a 
semirecumbent position on an adjustable chair with a cycle ergometer (model 828E; 
Monark Exercise AB, Vansbro, Sweden) positioned behind them. Resistance was created 
by applying friction to the flywheel, which was turned by the subject via a metal bar 
connecting the crank arm of the ergometer to a metal boot in which the subject’s foot was 
placed. Subjects exercised for 3 minutes at 0, 5, and 10 W maintaining 60 contractions 
per minute, with measurements and blood samples taken during the third minute of each 
stage. During the PE trial (Figure 4.1A), subjects exercised for an additional 2 minutes 
per stage during which PE was infused, with PE measurements taken during the second 





rate were divided into two separate 3-minute stages if the subject could not continuously 
exercise for the full 5 minutes. A 5-minute recovery period was given following each 
stage (Figure 4.1), with additional rest given to subjects who required it in order to 
complete the predetermined stages.  
Measurements  
Ultrasound Doppler assessments   
Measurements of CFA blood velocity and vessel diameter were performed in the 
infused leg using a Logiq 7 ultrasound Doppler system (GE Medical Systems, 
Milwaukee, WI) operating in duplex mode. The Logic 7 is equipped with a linear array 
transducer operating at an imaging frequency of 14 MHz. The CFA was insonated 2-3 cm 
proximal to the bifurcation of the CFA into the superficial and deep branches. The blood 
velocity profile was obtained using the same transducer with a Doppler frequency of 5 
MHz, operated in the high-pulsed repetition frequency mode (2-25 kHz). Care was taken 
to avoid aliasing the blood velocity spectra by using scale adjustments, especially during 
exercise. All blood velocity measurements were obtained with the probe appropriately 
positioned to maintain an insonation angle of 60° or less (26). The sample volume was 
maximized according to vessel size and was centered within the vessel on the basis of 
real-time ultrasound visualization. At all sample points, arterial diameter (cm) and angle-
corrected, time-averaged, and intensity-weighted mean blood velocity (Vmean; cm/sec) 
values were calculated using commercially available software (Logic 7). Using measured 
arterial diameter and Vmean, leg blood flow was calculated according to the equation:  





Blood pressure, vascular conductance, and heart rate assessment   
Arterial and venous blood pressure measurements were collected continuously 
from the indwelling catheters placed in the CFA and CFV with the pressure transducers 
placed at the level of the catheters (Transpac IV, Abbott Laboratories). Mean arterial 
pressure (MAP) was calculated as:  
MAP (mmHg) = diastolic arterial pressure + (arterial pulse pressure x 0.33)  
Leg perfusion pressure was calculated as:  
Leg perfusion pressure (mmHg) = MAP – venous pressure 
Leg vascular conductance was calculated as:  
Leg vascular conductance (ml/min/mmHg) = leg blood flow / leg perfusion 
pressure 
Heart rate (HR) was monitored from a standard 3-lead ECG recorded in duplicate on the 
data acquisition device (Biopac, Goleta, CA, U.S.A.) and the Logic 7. 
Blood chemistry   
A lipid panel was obtained for all subjects by standard techniques. In the last 30 
seconds of each exercise stage, femoral arterial and venous blood samples (3-4 ml) were 
collected. 1 ml of arterial and venous blood were presented anaerobically to a GEM 4000 
blood-gas analyzer and co-oximeter (Instrumentation Laboratories, Bedford, MA) to 





partial pressure of oxygen (PO2), and hematocrit (hct). Arterial and venous blood oxygen 
(O2) content (CaO2 and CvO2) was calculated as:  
Blood O2 content (ml/dl) = 1.39 (tHb) * (SO2/100) + 0.003 * PO2 
Leg O2 delivery was calculated as:  
Leg O2 delivery (ml/min) = Leg blood flow * CaO2 
Leg O2 consumption (VO2) was calculated as:  
Leg VO2 (ml/min) = (CaO2 − CvO2) * leg blood flow 
The remaining blood was centrifuged, and plasma was stored at -80°C for plasma 
catecholamine analysis. Plasma NE and Epi concentrations were measured in duplicate 
by competitive ELISA (2-CAT ELISA; Labor Diagnostika Nord GmbH & Co. KG, 
Nordhorn, Germany). Using arterial (CA) and venous (CV) plasma NE and EPi 
concentrations, with corrections for leg blood flow, the rate of NE spillover was 
calculated according to the following equation (37, 38):  
NE spillover (ng/min) = [(Cv – Ca) + Ca*(EPie)] * (leg blood flow * ((101 – (hct/100)) 









Drug-induced changes were calculated as:  
Drug-induced change () = drug trial value – pre-infusion value 
or:  
Drug-induced change (%) = (drug-induced change () / pre-infusion value) *100 
When comparing exercise to resting drug-induced changes for the PE trial, the response 
to the fourth dose of the PE dose response was always used as this dose was similar to the 
concentration of drug infused during exercise. The control condition (i.e. pre-infusion) in 
which the exercise portion of PHEN trial was compared to was the pre-infusion portion 
of the PE trial (Figure 4.1). Statistics were performed using commercially available 
software (SigmaStat 3.10; Systat Software, Point Richmond, CA), repeated measures 
ANOVA (α < 0.05), and Student t-tests (α < 0.05) were used to identify significant 
changes in measured variables within and between drug groups and across exercise 
intensities. A Person Product Moment Correlation (α < 0.05) was performed to evaluate 
the association between leg O2 delivery at 10 W and each subject’s respective relative 
exercise intensity at 10 W of single-leg KE exercise. The Holm-Sidak method was used 








Subject Characteristics  
Baseline characteristics of the control subjects and HFrEF patients are displayed 
in Table 4.1. Disease-specific characteristics and medications of patients with HFrEF are 
presented in Table 4.2.   
Beta-Adrenergic Receptor Antagonism 
  Beta-adrenergic receptor antagonism by intravenous-infusion of propranolol 
induced a significant reduction in HR, leg blood flow, and leg vascular conductance, with 
no marked change in leg perfusion pressure or CFA diameter in control subjects (Table 
4.3).  
Alpha-1-Adrenergic Receptor Responsiveness at Rest  
In both the control and HFrEF groups, the administration of the alpha-1-
adrenergic receptor agonist PE did not significantly change HR or perfusion pressure 
with increasing concentrations of the drug (Table 4.3). PE did provoke significant, dose-
dependent reductions in leg blood flow, leg vascular conductance, and CFA in both 
groups (Figures 4.2, 4.4, and Table 4.3). However, compared to the control group, the 
HFrEF patients exhibited a significantly smaller reduction in leg blood flow and leg 
vascular (Figure 4.2 and Table 4.3) induced by PE infusion.  
Nonselective Alpha-Adrenergic Receptor Antagonism at Rest 
 After 10 minutes of continuous infusion of PHEN, no significant changes in HR 
or leg perfusion pressure were observed in either group (Table 4.4). Both groups 





response to PHEN (Figures 4.3 and 4.4). However, the increases in these variables were 
significantly greater in HFrEF. Additionally, HFrEF patients exhibited a significantly 
greater increase in CFA diameter compared to control subjects (Table 4.4). 
Cardiovascular Responses to Exercise  
Intensity-dependent increases in leg blood flow, leg vascular conductance, and leg 
perfusion pressure were observed in both groups (Figures 4.3A and 4.4A). However, 
both the vasodilatory and hyperemic responses were attenuated in HFrEF patients 
compared to the control group (Figures 4.3A and 4.4A, top and middle). This 
attenuated hyperemic response across work rates in HFrEF patients contributed to a 
significantly lower leg O2 delivery (Figure 4.6A, top). In HFrEF patients, the attenuation 
in leg O2 delivery at 10 W was negatively associated with each subject’s respective 
relative exercise intensity at 10 W, an association which was not present in the control 
group (Figure 4.7). Additionally, the attenuated O2 delivery and an attenuated leg 
arterial-venous O2 difference (Table 4.5) contributed to an attenuated leg VO2 (Figure 
4.6A, bottom) in HFrEF.  In both groups, NE spillover increases in an intensity-
dependent manner in both groups (Table 4.5). While these values were not significantly 
different between groups, the HFrEF patients tended to have higher levels of NE spillover 








Alpha-1-Adrenergic Responsiveness During Exercise  
No significant changes in HR or leg perfusion pressure were observed after PE 
infusion (Table 4.5). PE significantly reduced leg blood flow and leg vascular 
conductance in both groups across increasing exercise intensities (Figure 4.4A, top and 
middle). Similar PE-induced changes in leg blood flow and leg vascular conductance 
were also observed in both groups (Figure 4.4B, top and middle). However, PE-induced 
changes were attenuated compared to rest only in the control group (Figure 4.4B, top 
and middle). Interestingly, PE only significantly reduced CFA diameter in the HFrEF 
group during exercise (Table 4.5), and the level of CFA vasoconstriction in HFrEF was 
not different than the level of vasoconstriction observed at rest across exercise intensities 
(Table 4.5). 
Nonselective Alpha-Adrenergic Antagonism During Exercise  
No significant changes in HR were observed between pre-infusion values and 
PHEN in either group (Table 4.5). PHEN infusion contributed to a reduction in leg 
perfusion pressure in the control group (Figure 4.5, bottom), while no significant 
changes in leg perfusion pressure were exhibited in the HFrEF group (Figure 4.5, 
bottom). PHEN significantly increased leg blood flow and vascular conductance in both 
groups (Figure 4.5A, top and middle), with the changes in leg blood flow and leg 
vascular conductance significantly greater in the HFrEF patients compared to control 
subjects (Figure 4.5B, top and middle). Despite the significant increases in leg blood 
flow and vascular conductance, these changes were significantly less than the response 
observed at rest in both groups (Figure 4.5B, top and middle).  In the control group, the 





O2 difference (Table 4.5), contributed to similar leg VO2 values in the PHEN trial 
compared to pre-infusion values (Figure 4.6, bottom). While the HFrEF patients also 
exhibited a reduction in leg arterial-venous O2 difference induced by PHEN (Table 4.5), 
the PHEN-induced increase in leg blood flow was substantial enough to significantly 
increase leg VO2 in this group (Figure 4.6, bottom).  Following PHEN infusion, NE 
spillover was increased in both groups; however, only the control group demonstrated 
significantly greater values compare to pre-infusion values (Table 4.5).  
Discussion 
The present study sought to comprehensively examine the importance of alpha-
adrenergic receptor-mediated vasoconstriction in the skeletal muscle vasculature of 
HFrEF patients compared to age-matched control subjects at rest and during exercise. At 
rest, vasoconstriction in response to intra-arterial infusion of PE was significantly 
reduced in HFrEF patients, suggesting a disease-related reduction in alpha-1-adrenergic 
receptor responsiveness. Alpha-adrenergic receptor antagonism induced by intra-arterial 
infusion of PHEN elicited a greater vasodilation and increase in blood flow in HFrEF 
patients compared to controls, supporting the concept of exaggerated sympathetic 
restraint of resting leg blood flow in this patient group. During exercise, PE-induced 
vasoconstriction and reduction in leg blood flow were reduced compared to rest in the 
control group. In contrast, vasoconstriction to PE was unchanged from resting responses 
in HFrEF patients, suggesting that the sympatholytic effect of exercise is impaired in this 
cohort. Additionally, PHEN infusion during exercise increased leg blood flow to a greater 
degree in the HFrEF group compared to controls, indicating a greater sympathetic 





flow and the accompanying elevation in O2 delivery increased leg VO2 in HFrEF patients, 
a response not present in the control group. Together, these findings implicate disease-
related changes in the alpha-adrenergic receptor pathway as an important maladaptive 
process that restrains skeletal muscle blood flow and O2 delivery, and may therefore 
contribute to diminished exercise capacity and exaggerated exercise intolerance in this 
patient group. 
Alpha-Adrenergic Receptor Regulation at Rest  
Though HFrEF patients present with a host of symptoms related to cardiac 
dysfunction, perhaps one of the most detrimental consequences of the disease is an 
elevation in SNS activity (25), which has implications in both the progression of HFrEF 
and mortality of these patients (11). One of the most deleterious effects of heightened 
sympathoexcitation is the end-organ (i.e. alpha-adrenergic receptor) expression in the 
peripheral circulation, resulting in a substantial restraint of skeletal muscle blood flow 
(12). Thus, one of the primary goals of the present study was to determine the role of the 
alpha-adrenergic receptors in regulating skeletal muscle blood flow at rest in patients 
with HFrEF.    
In the resting leg, administration of PE resulted in significant vasoconstriction in 
both groups. However, the magnitude of the PE-induced reduction in leg blood flow 
(Figure 4.2, top) and leg vascular conductance (Figure 4.2, bottom) were significantly 
blunted in HFrEF compared with control subjects, suggesting a disease-related reduction 
in alpha-1 receptor responsiveness in HFrEF patients. These findings are in contrast to 
one of the only previous human studies to examine alpha-1-mediated vasoconstriction in 





(18) identified similar reductions in forearm blood flow in NYHA Class II-III HFrEF 
patients and young, healthy control subjects despite significantly higher concentrations of 
plasma NE in HFrEF patients. While the reasons for this discrepancy between the former 
and current studies are not immediately apparent, significant differences in methodology, 
drug dosing, and subject characteristics may explain the divergent findings observed in 
the present study. It is also noteworthy that the current study was performed in the leg, an 
important distinction considering the evidence for nonuniform distribution of alpha-
adrenergic receptors between limbs (31). Thus, using a wide range of drug doses that 
produced a clear “plateau” in vasoconstriction at the highest doses (Figure 4.2), we have 
identified for the first time a reduction in alpha-1-adrenergic receptor-mediated 
responsiveness in HFpEF patients.    
This observed reduction in alpha-1-adrenergic receptor responsiveness is 
congruent with studies in other populations with elevated SNS activity, where a 
downregulation and/or desensitization of alpha-adrenergic receptors is observed in 
response to chronic sympathoexcitation. For example, in the elderly, a population in 
which SNS activity is also increased (15, 29, 45), our group (54) and others (14, 40) have 
observed a blunted alpha-adrenergic receptor vasoconstriction following intra-arterial 
sympathomimetic drug infusions, which likely represents a protective response to the 
200-300% increase in resting SNS activity often reported with advancing age. Likewise, 
it is tempting to speculate that the observed attenuation of the responsiveness of alpha-1-
adrenergic receptors in HFrEF patients may be the consequence of a disease-associated 
increase in SNS activity (19, 25). However, determining whether this disease associated 





receptor sensitivity, density, or changes in receptor distribution is beyond the scope of 
present study.  
To further explore disease-related changes in the alpha-adrenergic receptor 
pathway, we also administered a nonselective alpha-adrenergic receptor antagonist 
(PHEN) to pharmacologically ablate endogenous alpha-adrenergic receptor tone in the 
resting leg. In support of our hypothesis, PHEN infusion induced a greater increase in leg 
blood flow (Figure 4.3, top) and leg vascular conductance (Figure 4.3, bottom) in 
HFrEF patients compared to controls. These responses are in agreement with work in a 
pacing-induced animal model of heart failure (HF), where intra-arterial infusion of PHEN 
increased resting hindlimb vascular conductance by 50% in healthy control animals and 
226% in HF animals (43). Similar observations have been demonstrated in humans. Zelis 
et al. (57) reported a greater percent increase in forearm blood flow in response to 
brachial artery infusion of PHEN in patients with HFrEF compared to healthy control 
subjects (57). More recently, Alves et al. (1) performed a similar experiment and reported 
a significantly greater forearm vasodilation and corresponding increase in forearm blood 
flow in HFrEF patients compared to healthy age-matched control subjects. Thus, the 
current findings of an exaggerated vasodilation in response to “pharmacologic 
sympathectomy” in the skeletal muscle vasculature of the leg both confirms and extends 
previous work in HFrEF patients, supporting the concept that endogenous alpha-
adrenergic tone is elevated in this cohort.   
Cardiovascular Adjustments to Exercise in HFrEF  
It is well-established that patients with HFrEF suffer from an impaired capacity to 





hemodynamic regulation. Indeed, work by our group has identified an attenuated 
hyperemic response during dynamic single-leg KE exercise in this patient group which is 
related to work capacity (7). The present study extends these recent findings by 
identifying an impairment in O2 delivery which is negatively associated with the relative 
work performed at the highest exercise intensity (Figure 4.7), and when coupled with the 
attenuated leg arterial-venous O2 difference, contributes to an impairment in leg VO2 in 
this patient group (Figure 4.6). This is in agreement with Zelis et al. (57), who 
documented a blunted forearm VO2 during static-intermittent handgrip exercise in HFrEF 
patients. However, in this previous study, reduced arm VO2 was accompanied by a 
greater arterial-venous O2 difference in HFrEF patients compared to control subjects, 
suggestive of a potential limb-specific difference in O2 extraction during exercise in 
HFrEF patients. The present findings thus extend this previous work to the dynamic 
single-leg exercise modality, providing new evidence for a disease-related impairment in 
the hemodynamic response to small muscle mass exercise that contributes to a reduction 
in O2 delivery and VO2 in this patient group.  
 
Alpha-Adrenergic Receptor Regulation During Exercise  
During dynamic exercise, SNS activity increases in effort to redistribute blood 
flow and optimize perfusion of the exercise skeletal muscle (36). Considering that HFrEF 
patients experience an exaggerated increase in SNS activity during exercise (18), the 
alpha-adrenergic receptor pathway provides a logical starting point to probe the 
attenuated hyperemic response observed in this patient group during exercise. Indeed, 





exercising skeletal muscle, a phenomenon known as “functional sympatholysis” (32), is 
well-described in both animals (32) and humans (34, 52). However, until now, no studies 
have examined the sympatholytic effect of exercise in HFrEF.  
During exercise, we observed a significant reduction in leg blood flow (Figure 
4.4A, top) and leg vascular conductance (Figure 4.4A, middle) in response to PE 
administration in both groups across all work rates. However, when compared to the 
respective responses observed at rest, the control group demonstrated a “lysing” of alpha-
1-adrenergic receptor vasoconstriction (Figure 4.4B, top and middle), whereas the 
HFrEF patients demonstrated a preserved alpha-1-adrenergic receptor vasoconstrictor 
response (Figure 4.4B, top and middle). This new finding is in agreement with one of 
the only other studies to examine functional sympatholysis in HF. Using a coronary 
ligation model of HF in rats, Thomas et al. (47) examined changes in femoral artery 
vascular conductance in response to sympathetic stimulation during both a sham trial and 
involuntary contraction of the hindlimbs induced by electrical stimulation. The 
unequivocal finding from this study was that sympathetic vasoconstriction was 
persevered in these animals during hindlimb contraction compared to the sham trial, 
indicating an “impaired sympatholysis” in this animal model of HF. The present findings 
thus extend this former work to the HFrEF patient population, reporting for the first time 
a preserved alpha-adrenergic receptor vasoconstriction during exercise in this cohort.  
To further investigate sympathetic restraint of leg blood flow in HFrEF patients 
during exercise, alpha-adrenergic receptor antagonism was implemented through intra-
arterial infusion of PHEN. Compared to the pre-infusion condition, PHEN administration 





middle) in both groups across all work rates. However, somewhat unexpectedly, leg 
perfusion pressure was reduced in the control group during the PHEN trial, but remained 
unchanged in the HFrEF patients (Figure 4.5, bottom). Thus, in the control group, this 
reduction in perfusion pressure during exercise may have contributed to the attenuated 
increase in leg blood flow, somewhat overestimating the between-group differences in 
leg blood flow in response to PHEN (Figure 4.5, top). However, even when this pressure 
change was taken into account through calculation of leg vascular conductance (Figure 
4.5, middle), PHEN-induced changes during exercise remain significantly different 
between groups (main effect for group), particularly at the higher exercise intensities. 
Taken together, these data indicate a greater role and capacity of the alpha-adrenergic 
receptors in restraining blood flow, and ultimately O2 delivery, in this patient group.  
These changes in responses to alpha-adrenergic inhibition are in agreement with 
animal studies utilizing a similar pharmacologic approach in a pacing-induced HF model. 
Indeed, Stickland et al. (43) observed a substantially greater increase in hindlimb blood 
flow following PHEN administration during treadmill running in HF animals compared 
to control animals, indicating an augmented alpha-adrenergic receptor restraint of 
hindlimb blood flow. Compared to this observation in animals, the results in human HF 
are equivocal. Zelis et al. (57) reported that alpha-adrenergic receptor-mediated 
vasoconstriction plays a greater role in restraining blood flow during one moderate level 
of handgrip exercise in HFrEF patients compared to healthy controls, as documented by a 
larger increase in exercising forearm blood flow in response to intra-arterial infusion of 
PHEN. In contrast, Wilson et al. (50) demonstrated no change in leg blood flow when 





The present data build upon this earlier work through inclusion of a carefully matched 
control group, continuous drug infusion, and use of a the single-leg KE exercise modality 
at multiple work rates, identifying for the first time a significant sympathetic restraint of 
leg blood flow during exercise in HFrEF patients compared to controls.   
Alpha-Adrenergic Receptor Regulation of Leg Oxygen  
Consumption During Exercise   
While the increase in leg blood flow and leg vascular conductance following 
PHEN administration clearly identifies the importance of excess sympathetic 
vasoconstriction on exercise hyperemia in HFrEF, further insight into the functional 
significance of restricting blood flow may be gained by evaluating leg O2 delivery and 
consumption during exercise. Interestingly, after alpha-adrenergic receptor blockade, 
HFrEF patients demonstrated an increase in leg VO2, a response not present in the control 
group (Figure 4.6, bottom). This unique combination of elevated leg VO2 under the 
condition of increased O2 delivery after alpha-adrenergic inhibition suggests a decrease in 
intramuscular efficiency, defined as the ratio of mechanical output to metabolic cost 
calculated from VO2 (10, 41). At face value, a reduction in intramuscular efficiency 
might appear detrimental, especially in a patient group where being more efficient should 
be considered beneficial; however, a recent study from our group suggests otherwise. 
Indeed, using the novel technique of lumbar intrathecal injection of fentanyl to inhibit 
group III and IV afferent fibers in HFrEF patients during single-leg KE exercise, we 
observed an increase in leg O2 delivery and VO2 in conjunction with a substantial 
reduction in postexercise quadriceps muscle fatigue. Thus, it is tempting to speculate that 





adrenergic receptor blockade (Figures 4.5 and 4.6) may be outweighed by reduced 
fatigue and subsequent improvements in exercise tolerance in HFrEF patients, though 
additional studies are needed to directly examine this relationship.  
Functional Sympatholysis in HFrEF: A Tale of Two  
Pharmacological Strategies  
Conventionally, the concept of functional sympatholysis during exercise is 
studied using a “stimulatory approach” through the use of lumbar sympathetic 
stimulation in animal models (47), or through the pharmacological approach of local 
alpha-adrenergic receptor agonist drugs (9, 16, 53), with both approaches comparing the 
resting vasoconstrictor response to the response induced during muscular contraction or 
exercise (Figure 4.4). A complimentary approach is the use of alpha-adrenergic receptor 
antagonism to make comparisons with respect to the change in blood flow at rest and 
during exercise (Figure 4.5). While both of these pharmacological methods probe the 
role of the alpha-adrenergic receptors in the regulation of vascular tone and blood flow to 
the exercising skeletal muscle, they should be considered mutually exclusive, as both 
methods tell very different stories. Specifically, the stimulatory approach is informative 
regarding the level of vasoconstrictor reserve or “active vasoconstriction” (35) provided 
by the alpha-adrenergic system. Thus, if sympathetic vasoconstriction during exercise is 
lysed by metabolic inhibition or alpha-adrenergic receptor occupancy by NE, using a 
stimulatory approach will indicate to what extent the alpha-adrenergic receptors can 
further induce vasoconstriction and reduce blood flow. In contrast, alpha-adrenergic 
antagonism provides insight concerning the level of “passive vasodilation” (35), or the 





vascular tone and  blood flow both at rest and during exercise. Because of the different 
aspects of vascular control these two approaches unveil, the current study has 
comprehensively established the role and vasoconstrictor potential of the alpha-
adrenergic receptor pathway at rest and during exercise in this patient group.  
Conclusions  
This study has revealed a significant role of the alpha-adrenergic receptor 
pathway in restraining blood flow and O2 delivery to the exercising skeletal muscle in 
patients with HFrEF, a physiological maladaptation which might contribute to the evident 
exercise intolerance and limited capacity to perform tasks of everyday life present in this 




















1. Alves MJ, Rondon MU, Santos AC, Dias RG, Barretto AC, Krieger EM, 
Middlekauff HR, and Negrao CE. Sympathetic nerve activity restrains reflex 
vasodilatation in heart failure. Clin Auton Res 17: 364-369, 2007. 
2. Amann M, Runnels S, Morgan DE, Trinity JD, Fjeldstad AS, Wray DW, 
Reese VR, and Richardson RS. On the contribution of group III and IV muscle 
afferents to the circulatory response to rhythmic exercise in humans. J Physiol 589: 3855-
3866, 2011. 
3. Andersen P, Adams RP, Sjogaard G, Thorboe A, and Saltin B. Dynamic knee 
extension as model for study of isolated exercising muscle in humans. J Appl Physiol 
(1985) 59: 1647-1653, 1985. 
4. Andersen P, and Saltin B. Maximal perfusion of skeletal muscle in man. J 
Physiol 366: 233-249, 1985. 
5. Barden J, Lawrenson L, Poole JG, Kim J, Wray DW, Bailey DM, and 
Richardson RS. Limitations to vasodilatory capacity and .VO2 max in trained human 
skeletal muscle. Am J Physiol Heart Circ Physiol 292: H2491-2497, 2007. 
6. Barrett-O'Keefe Z, Ives SJ, Trinity JD, Morgan G, Rossman MJ, Donato AJ, 
Runnels S, Morgan DE, Gmelch BS, Bledsoe AD, Richardson RS, and Wray DW. 
Taming the "sleeping giant": the role of endothelin-1 in the regulation of skeletal muscle 
blood flow and arterial blood pressure during exercise. Am J Physiol Heart Circ Physiol 
304: H162-169, 2013. 
7. Barrett-O'Keefe Z, Lee JF, Berbert A, Witman MA, Nativi JN, Stehlik J, 
Richardson RS, and Wray DW. Hemodynamic Responses to Small Muscle Mass 
Exercise in Heart Failure Patients with Reduced Ejection Fraction. Am J Physiol Heart 
Circ Physiol 2014. 
8. Benge W, Litchfield RL, and Marcus ML. Exercise capacity in patients with 
severe left ventricular dysfunction. Circulation 61: 955-959, 1980. 
9. Buckwalter JB, Naik JS, Valic Z, and Clifford PS. Exercise attenuates alpha-
adrenergic-receptor responsiveness in skeletal muscle vasculature. J Appl Physiol (1985) 
90: 172-178, 2001. 
10. Cavanagh PR, and Kram R. The efficiency of human movement--a statement of 
the problem. Med Sci Sports Exerc 17: 304-308, 1985. 
11. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon 
AB, and Rector T. Plasma norepinephrine as a guide to prognosis in patients with 





12. Dargie H. Sympathetic activity and regional blood flow in heart failure. Eur 
Heart J 11 Suppl A: 39-43, 1990. 
13. Davis D, Baily R, and Zelis R. Abnormalities in systemic norepinephrine 
kinetics in human congestive heart failure. Am J Physiol 254: E760-766, 1988. 
14. Dinenno FA, Dietz NM, and Joyner MJ. Aging and forearm postjunctional 
alpha-adrenergic vasoconstriction in healthy men. Circulation 106: 1349-1354, 2002. 
15. Dinenno FA, Jones PP, Seals DR, and Tanaka H. Limb blood flow and 
vascular conductance are reduced with age in healthy humans: relation to elevations in 
sympathetic nerve activity and declines in oxygen demand. Circulation 100: 164-170, 
1999. 
16. Dinenno FA, Masuki S, and Joyner MJ. Impaired modulation of sympathetic 
alpha-adrenergic vasoconstriction in contracting forearm muscle of ageing men. J Physiol 
567: 311-321, 2005. 
17. Eklund B, and Kaijser L. Effect of regional alpha- and beta-adrenergic blockade 
on blood flow in the resting forearm during contralateral isometric handgrip. J Physiol 
262: 39-50, 1976. 
18. Esposito F, Mathieu-Costello O, Shabetai R, Wagner PD, and Richardson 
RS. Limited maximal exercise capacity in patients with chronic heart failure: partitioning 
the contributors. J Am Coll Cardiol 55: 1945-1954, 2010. 
19. Ferguson DW, Berg WJ, and Sanders JS. Clinical and hemodynamic correlates 
of sympathetic nerve activity in normal humans and patients with heart failure: evidence 
from direct microneurographic recordings. J Am Coll Cardiol 16: 1125-1134, 1990. 
20. Higginbotham MB, Morris KG, Conn EH, Coleman RE, and Cobb FR. 
Determinants of variable exercise performance among patients with severe left 
ventricular dysfunction. Am J Cardiol 51: 52-60, 1983. 
21. Indolfi C, Maione A, Volpe M, Rapacciuolo A, Esposito G, Ceravolo R, 
Rendina V, Condorelli M, and Chiariello M. Forearm vascular responsiveness to alpha 
1- and alpha 2-adrenoceptor stimulation in patients with congestive heart failure. 
Circulation 90: 17-22, 1994. 
22. Johnsson G, Nyberg G, and Solvell L. Influence of metoprolol and propranolol 
on hemodynamic effects induced by physical work and isoprenaline. Acta Pharmacol 
Toxicol (Copenh) 36: 69-75, 1975. 
23. Jones PR, and Pearson J. Anthropometric determination of leg fat and muscle 





24. Lawrenson L, Poole JG, Kim J, Brown C, Patel P, and Richardson RS. 
Vascular and metabolic response to isolated small muscle mass exercise: effect of age. 
Am J Physiol Heart Circ Physiol 285: H1023-1031, 2003. 
25. Leimbach WN, Jr., Wallin BG, Victor RG, Aylward PE, Sundlof G, and 
Mark AL. Direct evidence from intraneural recordings for increased central sympathetic 
outflow in patients with heart failure. Circulation 73: 913-919, 1986. 
26. Logason K, Barlin T, Jonsson ML, Bostrom A, Hardemark HG, and 
Karacagil S. The importance of Doppler angle of insonation on differentiation between 
50-69% and 70-99% carotid artery stenosis. Eur J Vasc Endovasc Surg 21: 311-313, 
2001. 
27. Metra M, Raddino R, Dei Cas L, and Visioli O. Assessment of peak oxygen 
consumption, lactate and ventilatory thresholds and correlation with resting and exercise 
hemodynamic data in chronic congestive heart failure. Am J Cardiol 65: 1127-1133, 
1990. 
28. Middlekauff HR, Chiu J, Hamilton MA, Fonarow GC, Maclellan WR, Hage 
A, Moriguchi J, and Patel J. Muscle mechanoreceptor sensitivity in heart failure. Am J 
Physiol Heart Circ Physiol 287: H1937-1943, 2004. 
29. Ng AV, Callister R, Johnson DG, and Seals DR. Age and gender influence 
muscle sympathetic nerve activity at rest in healthy humans. Hypertension 21: 498-503, 
1993. 
30. Notarius CF, Atchison DJ, and Floras JS. Impact of heart failure and exercise 
capacity on sympathetic response to handgrip exercise. Am J Physiol Heart Circ Physiol 
280: H969-976, 2001. 
31. Pawelczyk JA, and Levine BD. Heterogeneous responses of human limbs to 
infused adrenergic agonists: a gravitational effect? J Appl Physiol (1985) 92: 2105-2113, 
2002. 
32. Remensnyder JP, Mitchell JH, and Sarnoff SJ. Functional sympatholysis 
during muscular activity. Observations on influence of carotid sinus on oxygen uptake. 
Circ Res 11: 370-380, 1962. 
33. Richardson RS, and Saltin B. Human muscle blood flow and metabolism 
studied in the isolated quadriceps muscles. Med Sci Sports Exerc 30: 28-33, 1998. 
34. Rosenmeier JB, Dinenno FA, Fritzlar SJ, and Joyner MJ. alpha1- and alpha2-
adrenergic vasoconstriction is blunted in contracting human muscle. J Physiol 547: 971-
976, 2003. 
35. Rowell LB. Human circulation : regulation during physical stress. New York: 





36. Rowell LB. Ideas about control of skeletal and cardiac muscle blood flow (1876-
2003): cycles of revision and new vision. J Appl Physiol (1985) 97: 384-392, 2004. 
37. Savard G, Strange S, Kiens B, Richter EA, Christensen NJ, and Saltin B. 
Noradrenaline spillover during exercise in active versus resting skeletal muscle in man. 
Acta Physiol Scand 131: 507-515, 1987. 
38. Savard GK, Richter EA, Strange S, Kiens B, Christensen NJ, and Saltin B. 
Norepinephrine spillover from skeletal muscle during exercise in humans: role of muscle 
mass. Am J Physiol 257: H1812-1818, 1989. 
39. Silber DH, Sutliff G, Yang QX, Smith MB, Sinoway LI, and Leuenberger 
UA. Altered mechanisms of sympathetic activation during rhythmic forearm exercise in 
heart failure. J Appl Physiol 84: 1551-1559, 1998. 
40. Smith EG, Voyles WF, Kirby BS, Markwald RR, and Dinenno FA. Ageing 
and leg postjunctional alpha-adrenergic vasoconstrictor responsiveness in healthy men. J 
Physiol 582: 63-71, 2007. 
41. Stainbsy WN, Gladden LB, Barclay JK, and Wilson BA. Exercise efficiency: 
validity of base-line subtractions. J Appl Physiol Respir Environ Exerc Physiol 48: 518-
522, 1980. 
42. Sterns DA, Ettinger SM, Gray KS, Whisler SK, Mosher TJ, Smith MB, and 
Sinoway LI. Skeletal muscle metaboreceptor exercise responses are attenuated in heart 
failure. Circulation 84: 2034-2039, 1991. 
43. Stickland MK, Miller JD, Smith CA, and Dempsey JA. Carotid chemoreceptor 
modulation of regional blood flow distribution during exercise in health and chronic heart 
failure. Circ Res 100: 1371-1378, 2007. 
44. Sullivan MJ, and Hawthorne MH. Exercise intolerance in patients with chronic 
heart failure. Prog Cardiovasc Dis 38: 1-22, 1995. 
45. Sundlof G, and Wallin BG. Human muscle nerve sympathetic activity at rest. 
Relationship to blood pressure and age. J Physiol 274: 621-637, 1978. 
46. Szlachcic J, Massie BM, Kramer BL, Topic N, and Tubau J. Correlates and 
prognostic implication of exercise capacity in chronic congestive heart failure. Am J 
Cardiol 55: 1037-1042, 1985. 
47. Thomas GD, Zhang W, and Victor RG. Impaired modulation of sympathetic 
vasoconstriction in contracting skeletal muscle of rats with chronic myocardial 
infarctions: role of oxidative stress. Circ Res 88: 816-823, 2001. 
48. Thomas JA, and Marks BH. Plasma norepinephrine in congestive heart failure. 





49. Weber KT, Kinasewitz GT, Janicki JS, and Fishman AP. Oxygen utilization 
and ventilation during exercise in patients with chronic cardiac failure. Circulation 65: 
1213-1223, 1982. 
50. Wilson JR, Ferraro N, and Wiener DH. Effect of the sympathetic nervous 
system on limb circulation and metabolism during exercise in patients with heart failure. 
Circulation 72: 72-81, 1985. 
51. Wilson JR, Martin JL, Ferraro N, and Weber KT. Effect of hydralazine on 
perfusion and metabolism in the leg during upright bicycle exercise in patients with heart 
failure. Circulation 68: 425-432, 1983. 
52. Wray DW, Fadel PJ, Smith ML, Raven P, and Sander M. Inhibition of alpha-
adrenergic vasoconstriction in exercising human thigh muscles. J Physiol 555: 545-563, 
2004. 
53. Wray DW, Nishiyama SK, Donato AJ, Sander M, Wagner PD, and 
Richardson RS. Endothelin-1-mediated vasoconstriction at rest and during dynamic 
exercise in healthy humans. Am J Physiol Heart Circ Physiol 293: H2550-2556, 2007. 
54. Wray DW, Nishiyama SK, and Richardson RS. Role of {alpha}1-adrenergic 
vasoconstriction in the regulation of skeletal muscle blood flow with advancing age. Am J 
Physiol Heart Circ Physiol 296: H497-504, 2009. 
55. Wray DW, Uberoi A, Lawrenson L, and Richardson RS. Heterogeneous limb 
vascular responsiveness to shear stimuli during dynamic exercise in humans. J Appl 
Physiol (1985) 99: 81-86, 2005. 
56. Wray DW, Witman MA, Ives SJ, McDaniel J, Fjeldstad AS, Trinity JD, 
Conklin JD, Supiano MA, and Richardson RS. Progressive handgrip exercise: 
evidence of nitric oxide-dependent vasodilation and blood flow regulation in humans. Am 
J Physiol Heart Circ Physiol 300: H1101-1107, 2011. 
57. Zelis R, Longhurst J, Capone RJ, and Mason DT. A comparison of regional 
blood flow and oxygen utilization during dynamic forearm exercise in normal subjects 












Figure 4.1 Experimental timeline for phenylephrine (A) and phentolamine (B) infusion at 










Figure 4.2 Changes (%) in leg blood flow (top) and leg vascular conductance (bottom) 
in response to local, intra-arterial infusion of phenylephrine (PE) in control subjects and 
heart failure patients with reduced ejection fraction (HFrEF). * Significant difference 
















































































































Figure 4.3 Changes (%) in leg blood flow (top) and leg vascular conductance (bottom) 
in response to local, intra-arterial infusion of phentolamine (PHEN) in control subjects 
and heart failure patients with reduced ejection fraction (HFrEF). * Significant difference 





























































































Figure 4.4 Absolute values (A) of: Leg blood flow (top), leg vascular conductance 
(middle), and leg perfusion pressure (bottom) in control subjects and heart failure patients 
with reduced ejection fraction (HFrEF) at rest and during knee-extensor exercise in 
control conditions (pre-infusion) and during phenylephrine (PE) infusion. PE-induced 
changes (%) (B) of: leg blood flow (top), leg vascular conductance (middle), and leg 
perfusion pressure (bottom) in control subjects and HFrEF patients at rest and during 
knee-extensor exercise. * Significant difference from control, P<0.05; # Significant 
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Figure 4.5 Absolute values (A) of: Leg blood flow (top), leg vascular conductance 
(middle), and leg perfusion pressure (bottom) in control subjects and heart failure patients 
with reduced ejection fraction (HFrEF) at rest and during knee-extensor exercise in 
control conditions (pre-infusion) and during phentolamine (PHEN) infusion. PHEN-
induced changes (%) (B) of: Leg blood flow (top), leg vascular conductance (middle), 
and leg perfusion pressure (bottom) in control subjects and HFrEF patients at rest and 
during knee-extensor exercise. * Significant difference from control, P<0.05; # 














































































































































































Figure 4.6 Absolute values (A) of: Leg oxygen delivery (top), and leg oxygen 
consumption (bottom) in control subjects and heart failure patients with reduced ejection 
fraction (HFrEF) at rest and during knee-extensor exercise in control conditions (pre-
infusion) and during phentolamine (PHEN) infusion. PHEN-induced changes () (B) of: 
Leg oxygen delivery (top) and leg oxygen consumption (bottom) in control subjects and 
HFrEF patients at rest and during knee-extensor exercise. * Significant difference from 
control, P<0.05; # Significant difference from pre-infusion, P<0.05; † Significant 
























































































































































Figure 4.7 Relationship between leg oxygen delivery at 10 W and relative intensity at 10 
W during the control condition (pre-infusion) in control subjects and heart failure patients 
with reduced ejection fraction (HFrEF). Significant Pearson Product Moment Correlation 
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Table 4.1 Subject characteristics 
   Control (n = 8 )   HFrEF (n = 8 ) 
Age, yrs 63 ± 4  63 ± 4 
Height, cm 174 ± 3  174 ± 3 
Weight, kg 76 ± 6  82 ± 4 
Body mass index, kg/m2 25 ± 1 27 ± 1 
Thigh volume, L   7.7 ± 0.5   5.9 ± 0.1* 
Quadriceps muscle mass, kg   2.7 ± 0.1   2.2 ± 0.0* 
Systolic blood pressure, mmHg 120 ± 3  120 ± 6 
Diastolic blood pressure, mmHg  79 ± 2  77 ± 3 
Knee-extensor maximum, W   33 ± 6     18 ± 2* 
Glucose, mg/dl 86 ± 4  99 ± 8 
Total cholesterol, mg/dl 195 ± 14  139 ± 19* 
Triglycerides, mg/dl 117 ± 24  103 ± 10 
HDL, mg/dl 47 ± 4  37 ± 3 
LDL, mg/dl  131 ± 13  86 ± 15* 
HFrEF, heart failure with reduced ejection fraction; HDL, high density lipoprotein; 
LDL, low density lipoprotein.  Data are expressed as means ± SEM. * Significant 


















Table 4.2 Disease - specific characteristics and medications  
   HFrEF (n = 8) 
    
Disease-specific characteristics  
Left ventricular ejection fraction, % (means ± SEM)   30 ± 3 
Diagnosis (ischemic) 6 / 8 
Diagnosis (nonischemic) 2 / 8 
NYHA class II 4 / 8 
NYHA class III 4 / 8 
Diabetic  4 / 8 
    
Medications  
-Blocker 8 / 8 
ACE inhibitor 6 / 8 
Angiotensin receptor inhibitor  2 / 8 
Statin  7 / 8 
Diuretic 8 / 8 
Aldosterone inhibitor    2 / 8 
Digoxin   1 / 8 
Anticoagulant    7 / 8 
HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart 
















Table 4.3 Hemodynamic responses to propranolol and phenylephrine at rest 
      Phenylephrine (ug/min/dl thigh volume) 
Baseline Propranolol 0.015 0.03 0.06 0.12 0.24 
Control    
Leg blood flow, ml/min 253 ± 33  227 ± 33#  212 ± 33 185 ± 33# 174 ± 33# 142 ± 24# 141 ± 19# 
Leg vascular conductance , ml/min/mmHg 3.0 ± 0.4  2.7 ± 0.4# 2.5  ± 0.4 2.2 ± 0.4# 2.1 ± 0.4# 1.6 ± 0.3# 1.6 ± 0.2# 
Leg perfusion pressure, mmHg 85 ± 3  85 ± 3 83 ± 3 84 ± 3 85 ± 3 86 ± 3 87 ± 3 
Common femoral artery diameter, cm 1.02 ± 0.06 1.02 ± 0.06  1.01 ± 0.06 0.99 ± 0.06# 0.97 ± 0.07# 0.97 ± 0.07# 0.93 ± 0.7# 
Common femoral artery diameter, % - 0.0 ± 0.1 -0.6 ± 0.4  -3.0 ± 1.7 -4.8 ± 2.5# -6.8 ± 2.9# -9.6 ± 3.5# 
Heart rate, bpm 60 ± 4  54 ±  3# 54 ± 2 53 ± 3 53 ± 2 51 ± 2 52 ± 2 
        
HFrEF        
Leg blood flow, ml/min 218 ± 26 -  215 ± 20 202 ± 22 189 ± 19 179 ± 16# 174 ± 18# 
Leg vascular conductance, ml/min/mmHg 2.8 ±  0.3 - 2.8 ± 0.3 2.5 ± 0.3  2.3 ± 0.2# 2.2 ± 0.3# 2.1 ± 0.2# 
Leg perfusion pressure, mmHg 80 ± 5  - 80 ± 5 82 ± 5 82 ± 5 83 ± 4 82 ± 3 
Common femoral artery diameter, cm 0.88 ± 0.05 - 0.87 ± 0.05 0.86 ± 0.05 0.84 ± 0.05# 0.82 ± 0.05# 0.80 ± 0.06# 
Common femoral artery diameter, % - - -1.2 ± 0.3 -2.6 ± 0.6 -4.3 ± 0.8# -6.2 ± 1.0# -8.8 ± 2# 
Heart rate, bpm 67  ± 2  - 65 ± 2* 66 ± 3* 67 ± 2* 68 ± 3* 72 ± 6* 



















Table 4.4  Hemodynamic responses to infusions of  propranolol and 
phentolamine at rest 
Baseline Propranolol Phentolamine 
Control 
Leg blood flow, ml/min 234 ± 26 230 ± 27 477 ± 60# 
Leg vascular conductance, ml/min/mmHg 2.7 ± 0.3 2.7 ± 0.3 5.7 ± 0.6# 
Leg perfusion pressure, mmHg 87 ± 3 86 ± 4 84 ± 4 
Common femoral artery diameter, cm 1.02 ± 0.06 1.03 ± 0.05 1.05 ± 0.05 
Common femoral artery diameter, % - 1.1 ± 1.1 1.7 ± 1.2 
Heart rate, bpm 56 ± 3 54 ± 2 58 ± 3 
HFrEF 
Leg blood flow, ml/min 212 ± 24 - 557 ± 66# 
Leg vascular conductance, ml/min/mmHg 2.8 ± 0.3 - 7.4 ± 1.0*# 
Leg perfusion pressure, mmHg 79 ± 4 - 77 ± 4 
Common femoral artery diameter, cm 0.88 ± 0.05 - 0.91 ± 0.06# 
Common femoral artery diameter, % - - 4.1 ± 0.9# 
Heart rate, bpm 67 ± 3* - 67 ± 3* 
Data are expressed as means ± SEM.* Significant difference from control, P<0.05;                


















Table 4.5 Cardiovascular responses to intra-arterial infusions of phenylephrine and 
phentolamine at rest and during exercise 
Rest 0 W 5 W 10 W 
PRE-INFUSION 
Control 
Heart rate, bpm 55 ± 2 66 ± 3† 70 ± 5† 72 ± 5† 
Leg arterial-venous O2 difference, ml/dl 9.3 ± 1.3 15.4 ± 0.6† 15.4 ± 0.8† 16.0 ± 0.6† 
Norepinephrine spillover, ng/min 71 ± 16 384 ± 54† 417 ± 48† 426 ± 75† 
Common femoral artery diameter, cm 1.02 ± 0.05 1.02 ± 0.05 1.02 ± 0.05 1.02 ± 0.05 
HFrEF 
Heart rate, bpm 65 ± 3* 84 ± 5*† 86 ± 2*† 92 ± 3*† 
Leg arterial-venous O2 difference, ml/dl * 10.1 ± 0.6 12.7 ± 1.1† 13.4 ± 0.8† 13.4 ± 0.8† 
Norepinephrine spillover, ng/min 79 ± 22† 418 ± 163† 598 ± 248† 689 ± 144† 
Common femoral artery diameter, cm 0.88 ± 0.05 0.88 ± 0.05 0.88 ± 0.05 0.88 ± 0.05 
PHENYLEPHRINE 
Control 
Heart rate, bpm - 65 ± 4† 68 ± 6† 71 ± 5† 
Common femoral artery diameter, cm 0.95 ± 0.07# 1.00 ± 0.06† 1.00 ± 0.05† 1.01 ± 0.05† 
 Common femoral artery diameter, % -6.8 ± 2.9  -2.2 ± 0.7† -2.2 ± 0.6† -1.1 ± 0.5† 
HFrEF 
Heart rate, bpm - 81 ± 5*† 82 ± 4*† 89 ± 2*† 
Common femoral artery diameter, cm 0.82 ± 0.05 0.83 ± 0.05* 0.83 ± 0.05* 0.83 ± 0.05 
 Common femoral artery diameter, % -6.2 ± 1.0# -5.3 ± 1.2# -4.1 ± 1.3# -2.5 ± 1.0 
PHENTOLAMINE 
Control 
Heart rate, bpm 58 ± 3 68 ± 5† 74 ± 7† 75 ±6† 
Leg arterial-venous O2 difference, ml/dl 6.4 ± 1.6# 13.5 ± 0.8#† 13.6 ± 0.8#† 14.1 ± 0.7#† 
Norepinephrine spillover, ng/min 218 ± 28   982 ± 259#† 1105 ± 334#† 1030 ± 195#† 
Common femoral artery diameter, cm 1.05 ± 0.05 1.05 ± 0.05 1.05 ± 0.05 1.05 ± 0.05 
HFrEF 
Heart rate, bpm 67 ± 3* 83 ± 6† 88 ± 5† 97 ± 6*† 
Leg arterial-venous O2 difference, ml/dl # 5.6 ± 0.6 12.0 ± 0.7† 11.9 ± 0.9† 12.3 ± 0.6† 
Norepinephrine spillover, ng/min 221 ± 42 774 ± 230† 669 ± 206† 1062 ± 292† 
  Common femoral artery diameter, cm 0.91 ± 0.06# 0.91 ± 0.06# 0.91 ± 0.06# 0.91 ± 0.06# 
Data are expressed as means ± SEM. O2, oxygen.* Significant difference from control, P<0.05; # Significant 
































A hallmark characteristic of patients with HFrEF is a heightened sympathetic 
nervous system (SNS) activity, quantified by resting muscle sympathetic nerve activity 
(MSNA) (2, 4) and plasma norepinephrine concentration (3), both of which are 
associated with severity (2, 3) and predictive of mortality in HFrEF patients (1, 3). One of 
the principal functional consequences of the exaggerated SNS activation and subsequent 
peripheral vasoconstriction in patients with HFrEF might be the worsening of symptoms 
upon exertion. Indeed, previous studies exploring the possible relation between exercise 
intolerance in HFrEF and SNS activity indicated that resting MSNA is negatively 
associated with aerobic capacity in this cohort (6), and patients with HFrEF exhibit an 
exaggerated increase in MSNA during exercise (5, 7-9). These novel findings raise the 
question of the functional end-organ consequences of the persistent augmentation of 
MSNA during exercise in HFrEF. Thus, the purpose of the studies encompassing this 
dissertation was to systematically investigate the hemodynamic response to exercise in 
HFrEF and healthy controls of a similar age, with an emphasis on how SNS overactivity 
may contribute to dysregulation of the cardiovascular system in this cohort. 
In the first study, we aimed to determine how varying levels of metaboreceptor 
activation alter the mean arterial pressure (MAP) response, as well as the degree to which 
cardiac output (CO) and systemic vascular conductance (SVC) contribute to the 
metaboreflex-induced pressor response. Across workloads, the metaboreflex-induced 
increase in MAP was similar between groups. In controls, this was driven by increases in 
CO; however, in HFrEF, this change was accomplished by reductions in SVC, which 
contributed to an exaggerated increase in effective arterial elastance which was 
associated with an attenuated increase in stroke work in the patient group. Together, these 
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findings indicate a preserved role of the metaboreflex-induced pressor response in 
HFrEF, but suggest that this response is governed by the peripheral circulation, a 
maladaptation that may exacerbate existing systolic dysfunction in this cohort.  
The objective of the second study was to evaluate the hemodynamic responses to 
small muscle mass exercise in HFrEF patients and healthy control subjects of a similar 
age. During HG exercise, at 15% maximum voluntary contraction (MVC), forearm blood 
flow was similar between groups, while HFrEF patients exhibited an attenuated increase 
at the two highest intensities compared to control subjects, with the greatest difference at 
the highest workload. During knee-extensor exercise, HFrEF patients exhibited a 
diminished leg hyperemic response across all work rates. Together, these findings 
indicate a marked attenuation in exercising limb perfusion attributable to impairments in 
peripheral vasodilatory capacity during both arm and leg exercise in patients with HFrEF, 
which likely plays a role in limiting exercise capacity in this patient population.     
The objective of the third study was to investigate what role the alpha-adrenergic 
receptors play in restraining leg blood flow to the exercising limb in patients with HFrEF 
and age-matched control subjects. At rest, HFrEF patients exhibited an attenuated 
vasoconstrictor response to the local intra-arterial infusion of the alpha-1 adrenergic 
receptor agonist phenylephrine (PE). During exercise, the responsiveness to PE was 
blunted compared to rest in control subjects, but preserved in HFrEF patients. 
Additionally, HFrEF patients exhibited an enhanced alpha-adrenergic receptor restraint of 
limb blood flow, as demonstrated by the enhanced hyperemic response induced by the 
nonspecific alpha-adrenergic receptor antagonist phentolamine (PHEN) both at rest and 
during exercise. Together, this study indicates that alpha-adrenergic receptor restraint of 
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leg blood flow is upregulated at rest during exercise in patients with HFrEF and 
potentially contributes to the impaired exercise capacity exhibited to this patient group.      
 It is of utmost importance that we understand and study the cardiovascular 
response to exercise in patients with HFrEF in order to investigate therapeutic avenues to 
improve symptom status in this patient population during exercise. Findings from the 
studies contained herein may help to achieve this goal, by demonstrating the 
cardiovascular maladaptations associated with this disease and the role the SNS plays.  
We propose that the findings regarding the SNS demonstrate the potential for further 
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